{"id":16676,"date":"2024-09-27T19:00:30","date_gmt":"2024-09-27T17:00:30","guid":{"rendered":"https:\/\/inmuno.es\/?page_id=16676"},"modified":"2024-09-27T19:05:40","modified_gmt":"2024-09-27T17:05:40","slug":"current-opinion-immunology","status":"publish","type":"page","link":"https:\/\/inmuno.es\/index.php\/current-opinion-immunology\/","title":{"rendered":"Current Opinion in Immunology"},"content":{"rendered":"<ul class=\"wp-block-latest-posts__list is-grid columns-4 has-dates has-author wp-block-latest-posts is-layout-flow wp-block-latest-posts-is-layout-flow\"><li><a class=\"wp-block-latest-posts__post-title\" href=\"https:\/\/inmuno.es\/index.php\/2026\/09\/11\/a-systematic-review-of-juvenile-dermatomyositis-complicated-by-macrophage-activation-syndrome\/\">A systematic review of juvenile dermatomyositis complicated by macrophage activation syndrome<\/a><div class=\"wp-block-latest-posts__post-author\">by inmunoadmin<\/div><time datetime=\"2026-09-11T06:21:00+02:00\" class=\"wp-block-latest-posts__post-date\">11 de September de 2026<\/time><div class=\"wp-block-latest-posts__post-excerpt\">Curr Opin Immunol. 2026 Sep 10;103:102834. doi: 10.1016\/j.coi.2026.102834. Online ahead of print. ABSTRACT BACKGROUND: Macrophage activation syndrome (MAS) is a rare but potentially life-threatening complication of juvenile dermatomyositis (JDM). Data on its clinical presentation, diagnosis, treatment, and outcomes remain limited. OBJECTIVE: To systematically review the literature on MAS occurring in patients with JDM. METHODS: A &#8230; <a title=\"A systematic review of juvenile dermatomyositis complicated by macrophage activation syndrome\" class=\"read-more\" href=\"https:\/\/inmuno.es\/index.php\/2026\/09\/11\/a-systematic-review-of-juvenile-dermatomyositis-complicated-by-macrophage-activation-syndrome\/\" aria-label=\"Read more about A systematic review of juvenile dermatomyositis complicated by macrophage activation syndrome\">Read more<\/a><\/div><\/li>\n<li><a class=\"wp-block-latest-posts__post-title\" href=\"https:\/\/inmuno.es\/index.php\/2026\/09\/11\/complement-inhibition-in-pediatric-anca-associated-vasculitis\/\">Complement inhibition in pediatric ANCA-associated vasculitis<\/a><div class=\"wp-block-latest-posts__post-author\">by inmunoadmin<\/div><time datetime=\"2026-09-11T06:21:00+02:00\" class=\"wp-block-latest-posts__post-date\">11 de September de 2026<\/time><div class=\"wp-block-latest-posts__post-excerpt\">Curr Opin Immunol. 2026 Sep 10;103:102839. doi: 10.1016\/j.coi.2026.102839. Online ahead of print. ABSTRACT Antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) in childhood is a rare but severe condition associated with significant morbidity and treatment-related toxicity. Current therapies mainly rely on high-dose glucocorticoids and conventional immunosuppressants, which may cause substantial long-term adverse effects in pediatric patients. Advances &#8230; <a title=\"Complement inhibition in pediatric ANCA-associated vasculitis\" class=\"read-more\" href=\"https:\/\/inmuno.es\/index.php\/2026\/09\/11\/complement-inhibition-in-pediatric-anca-associated-vasculitis\/\" aria-label=\"Read more about Complement inhibition in pediatric ANCA-associated vasculitis\">Read more<\/a><\/div><\/li>\n<li><a class=\"wp-block-latest-posts__post-title\" href=\"https:\/\/inmuno.es\/index.php\/2026\/09\/10\/corrigendum-to-use-of-synthetic-data-a-novel-paradigm-for-immunopathology-curr-opin-immunol-2026100102753\/\">Corrigendum to &#8220;Use of synthetic data, a novel paradigm for immunopathology&#8221; [Curr Opin Immunol 2026;100:102753]<\/a><div class=\"wp-block-latest-posts__post-author\">by inmunoadmin<\/div><time datetime=\"2026-09-10T06:06:04+02:00\" class=\"wp-block-latest-posts__post-date\">10 de September de 2026<\/time><div class=\"wp-block-latest-posts__post-excerpt\">Curr Opin Immunol. 2026 Sep 8;103:102837. doi: 10.1016\/j.coi.2026.102837. Online ahead of print. NO ABSTRACT PMID:42715888 | DOI:10.1016\/j.coi.2026.102837<\/div><\/li>\n<li><a class=\"wp-block-latest-posts__post-title\" href=\"https:\/\/inmuno.es\/index.php\/2026\/08\/28\/spatiotemporal-dynamics-of-intestinal-immune-cells\/\">Spatiotemporal dynamics of intestinal immune cells<\/a><div class=\"wp-block-latest-posts__post-author\">by inmunoadmin<\/div><time datetime=\"2026-08-28T17:49:00+02:00\" class=\"wp-block-latest-posts__post-date\">28 de August de 2026<\/time><div class=\"wp-block-latest-posts__post-excerpt\">Curr Opin Immunol. 2026 Aug 27;102:102836. doi: 10.1016\/j.coi.2026.102836. Online ahead of print. ABSTRACT Intestinal immunity is coordinated by the spatial organization and temporal regulation of immune cells within a complex, antigen-rich environment. In this review, we discuss the latest advances in our understanding of how these two fundamental dimensions together shape intestinal immune homeostasis. We &#8230; <a title=\"Spatiotemporal dynamics of intestinal immune cells\" class=\"read-more\" href=\"https:\/\/inmuno.es\/index.php\/2026\/08\/28\/spatiotemporal-dynamics-of-intestinal-immune-cells\/\" aria-label=\"Read more about Spatiotemporal dynamics of intestinal immune cells\">Read more<\/a><\/div><\/li>\n<li><a class=\"wp-block-latest-posts__post-title\" href=\"https:\/\/inmuno.es\/index.php\/2026\/08\/15\/multimodal-and-fair-artificial-intelligence-in-paediatric-rheumatology-challenges-and-opportunities-for-a-holistic-and-equitable-future\/\">Multimodal and fair artificial intelligence in paediatric rheumatology: challenges and opportunities for a holistic and equitable future<\/a><div class=\"wp-block-latest-posts__post-author\">by inmunoadmin<\/div><time datetime=\"2026-08-15T05:51:11+02:00\" class=\"wp-block-latest-posts__post-date\">15 de August de 2026<\/time><div class=\"wp-block-latest-posts__post-excerpt\">Curr Opin Immunol. 2026 Aug 14;102:102835. doi: 10.1016\/j.coi.2026.102835. Online ahead of print. ABSTRACT Multimodal artificial intelligence (AI) is an emerging domain comprising a set of tools with potential clinical relevance in paediatric rheumatology, a field characterised by rare, heterogeneous diseases and diagnostic delays. This narrative review synthesises current evidence on how multimodal and fair AI &#8230; <a title=\"Multimodal and fair artificial intelligence in paediatric rheumatology: challenges and opportunities for a holistic and equitable future\" class=\"read-more\" href=\"https:\/\/inmuno.es\/index.php\/2026\/08\/15\/multimodal-and-fair-artificial-intelligence-in-paediatric-rheumatology-challenges-and-opportunities-for-a-holistic-and-equitable-future\/\" aria-label=\"Read more about Multimodal and fair artificial intelligence in paediatric rheumatology: challenges and opportunities for a holistic and equitable future\">Read more<\/a><\/div><\/li>\n<li><a class=\"wp-block-latest-posts__post-title\" href=\"https:\/\/inmuno.es\/index.php\/2026\/08\/04\/beyond-randomized-clinical-trials-in-pediatric-rheumatology-exploring-the-potential-of-target-trial-emulation\/\">Beyond randomized clinical trials in pediatric rheumatology: exploring the potential of target trial emulation<\/a><div class=\"wp-block-latest-posts__post-author\">by inmunoadmin<\/div><time datetime=\"2026-08-04T07:31:01+02:00\" class=\"wp-block-latest-posts__post-date\">4 de August de 2026<\/time><div class=\"wp-block-latest-posts__post-excerpt\">Curr Opin Immunol. 2026 Aug 3;102:102832. doi: 10.1016\/j.coi.2026.102832. Online ahead of print. ABSTRACT Real-world data (RWD) from nonrandomized clinical settings, such as registries and observational cohorts, can be used to address research questions for which randomized controlled trials (RCTs) are not feasible or appropriate. However, these data are susceptible to important sources of bias, including &#8230; <a title=\"Beyond randomized clinical trials in pediatric rheumatology: exploring the potential of target trial emulation\" class=\"read-more\" href=\"https:\/\/inmuno.es\/index.php\/2026\/08\/04\/beyond-randomized-clinical-trials-in-pediatric-rheumatology-exploring-the-potential-of-target-trial-emulation\/\" aria-label=\"Read more about Beyond randomized clinical trials in pediatric rheumatology: exploring the potential of target trial emulation\">Read more<\/a><\/div><\/li>\n<li><a class=\"wp-block-latest-posts__post-title\" href=\"https:\/\/inmuno.es\/index.php\/2026\/08\/01\/recurrent-pericarditis-in-children-evidence-controversies-and-emerging-perspectives\/\">Recurrent pericarditis in children: evidence, controversies, and emerging perspectives<\/a><div class=\"wp-block-latest-posts__post-author\">by inmunoadmin<\/div><time datetime=\"2026-08-01T07:31:17+02:00\" class=\"wp-block-latest-posts__post-date\">1 de August de 2026<\/time><div class=\"wp-block-latest-posts__post-excerpt\">Curr Opin Immunol. 2026 Jul 31;102:102833. doi: 10.1016\/j.coi.2026.102833. Online ahead of print. ABSTRACT Recurrent pericarditis complicates approximately one-third of initial pericarditis episodes in children. Once considered a postinfectious sequel, it is now understood as an autoinflammatory disorder sustained by dysregulated interleukin-1 signaling and inflammasome hyperactivation. This review evaluates therapeutic strategies for idiopathic recurrent pericarditis in &#8230; <a title=\"Recurrent pericarditis in children: evidence, controversies, and emerging perspectives\" class=\"read-more\" href=\"https:\/\/inmuno.es\/index.php\/2026\/08\/01\/recurrent-pericarditis-in-children-evidence-controversies-and-emerging-perspectives\/\" aria-label=\"Read more about Recurrent pericarditis in children: evidence, controversies, and emerging perspectives\">Read more<\/a><\/div><\/li>\n<li><a class=\"wp-block-latest-posts__post-title\" href=\"https:\/\/inmuno.es\/index.php\/2026\/07\/31\/emerging-principles-in-spatial-functional-genomics\/\">Emerging Principles in Spatial Functional Genomics<\/a><div class=\"wp-block-latest-posts__post-author\">by inmunoadmin<\/div><time datetime=\"2026-07-31T07:11:31+02:00\" class=\"wp-block-latest-posts__post-date\">31 de July de 2026<\/time><div class=\"wp-block-latest-posts__post-excerpt\">Curr Opin Immunol. 2026 Jul 30;102:102814. doi: 10.1016\/j.coi.2026.102814. Online ahead of print. ABSTRACT Spatial transcriptomic and proteomic atlases have enabled mapping of gene programs within intact tissues, but these measurements remain largely descriptive and do not define the mechanisms controlling tissue biology. Pooled CRISPR screening provides scalable causal interrogation of gene function but remains largely &#8230; <a title=\"Emerging Principles in Spatial Functional Genomics\" class=\"read-more\" href=\"https:\/\/inmuno.es\/index.php\/2026\/07\/31\/emerging-principles-in-spatial-functional-genomics\/\" aria-label=\"Read more about Emerging Principles in Spatial Functional Genomics\">Read more<\/a><\/div><\/li>\n<li><a class=\"wp-block-latest-posts__post-title\" href=\"https:\/\/inmuno.es\/index.php\/2026\/07\/30\/spatial-metabolic-heterogeneity-shapes-cd8-t-cell-function-in-cancer\/\">Spatial metabolic heterogeneity shapes CD8+ T cell function in cancer<\/a><div class=\"wp-block-latest-posts__post-author\">by inmunoadmin<\/div><time datetime=\"2026-07-30T06:52:43+02:00\" class=\"wp-block-latest-posts__post-date\">30 de July de 2026<\/time><div class=\"wp-block-latest-posts__post-excerpt\">Curr Opin Immunol. 2026 Jul 29;102:102829. doi: 10.1016\/j.coi.2026.102829. Online ahead of print. ABSTRACT Tumors are spatially heterogeneous ecosystems in which malignant, stromal, vascular, and immune cells interact within metabolically distinct niches. These localized microenvironments are shaped by factors such as nutrient availability, hypoxia, acidosis, and immunomodulatory metabolites, all of which strongly influence CD8\u207a T cell &#8230; <a title=\"Spatial metabolic heterogeneity shapes CD8+ T cell function in cancer\" class=\"read-more\" href=\"https:\/\/inmuno.es\/index.php\/2026\/07\/30\/spatial-metabolic-heterogeneity-shapes-cd8-t-cell-function-in-cancer\/\" aria-label=\"Read more about Spatial metabolic heterogeneity shapes CD8+ T cell function in cancer\">Read more<\/a><\/div><\/li>\n<li><a class=\"wp-block-latest-posts__post-title\" href=\"https:\/\/inmuno.es\/index.php\/2026\/07\/29\/from-rheumatology-to-dermatology-cytokine-signaling-pathways-as-therapeutic-targets-at-the-skin-joint-interface-in-inflammatory-diseases-a-narrative-review\/\">From rheumatology to dermatology: cytokine signaling pathways as therapeutic targets at the skin-joint interface in inflammatory diseases: a narrative review<\/a><div class=\"wp-block-latest-posts__post-author\">by inmunoadmin<\/div><time datetime=\"2026-07-29T01:30:03+02:00\" class=\"wp-block-latest-posts__post-date\">29 de July de 2026<\/time><div class=\"wp-block-latest-posts__post-excerpt\">Curr Opin Immunol. 2026 Jul 28;102:102830. doi: 10.1016\/j.coi.2026.102830. Online ahead of print. ABSTRACT Over the last two years, inflammatory dermatology has undergone a transition from morphology-based classification toward pathway-driven immune endotyping. Atopic dermatitis, psoriatic disease, and hidradenitis suppurativa have emerged as paradigmatic models of this transition, illustrating how epithelial dysfunction, involving autoinflammation and adaptive immunity, &#8230; <a title=\"From rheumatology to dermatology: cytokine signaling pathways as therapeutic targets at the skin-joint interface in inflammatory diseases: a narrative review\" class=\"read-more\" href=\"https:\/\/inmuno.es\/index.php\/2026\/07\/29\/from-rheumatology-to-dermatology-cytokine-signaling-pathways-as-therapeutic-targets-at-the-skin-joint-interface-in-inflammatory-diseases-a-narrative-review\/\" aria-label=\"Read more about From rheumatology to dermatology: cytokine signaling pathways as therapeutic targets at the skin-joint interface in inflammatory diseases: a narrative review\">Read more<\/a><\/div><\/li>\n<li><a class=\"wp-block-latest-posts__post-title\" href=\"https:\/\/inmuno.es\/index.php\/2026\/07\/28\/cardiac-sarcoidosis-from-early-recognition-to-management\/\">Cardiac sarcoidosis: from early recognition to management<\/a><div class=\"wp-block-latest-posts__post-author\">by inmunoadmin<\/div><time datetime=\"2026-07-28T07:17:02+02:00\" class=\"wp-block-latest-posts__post-date\">28 de July de 2026<\/time><div class=\"wp-block-latest-posts__post-excerpt\">Curr Opin Immunol. 2026 Jul 27;102:102831. doi: 10.1016\/j.coi.2026.102831. Online ahead of print. ABSTRACT Cardiac sarcoidosis is a potentially fatal inflammatory disorder with the tendency to mostly affect the myocardial tissues. It is commonly associated with extra-cardiac structures such as the lungs and the thoracic lymph nodes; however, when it manifests as an isolated disease, it &#8230; <a title=\"Cardiac sarcoidosis: from early recognition to management\" class=\"read-more\" href=\"https:\/\/inmuno.es\/index.php\/2026\/07\/28\/cardiac-sarcoidosis-from-early-recognition-to-management\/\" aria-label=\"Read more about Cardiac sarcoidosis: from early recognition to management\">Read more<\/a><\/div><\/li>\n<li><a class=\"wp-block-latest-posts__post-title\" href=\"https:\/\/inmuno.es\/index.php\/2026\/07\/25\/human-endogenous-retroviruses-leading-to-autoimmune-diseases\/\">Human endogenous retroviruses leading to autoimmune diseases<\/a><div class=\"wp-block-latest-posts__post-author\">by inmunoadmin<\/div><time datetime=\"2026-07-25T07:02:05+02:00\" class=\"wp-block-latest-posts__post-date\">25 de July de 2026<\/time><div class=\"wp-block-latest-posts__post-excerpt\">Curr Opin Immunol. 2026 Jul 24;102:102828. doi: 10.1016\/j.coi.2026.102828. Online ahead of print. ABSTRACT Human endogenous retroviruses (HERVs) comprise approximately 8% of the human genome and were long regarded as inert remnants of ancestral retroviral infections. Increasing evidence indicates that HERVs are active genomic elements capable of influencing transcriptional programs, modulating immune responses, and contributing to &#8230; <a title=\"Human endogenous retroviruses leading to autoimmune diseases\" class=\"read-more\" href=\"https:\/\/inmuno.es\/index.php\/2026\/07\/25\/human-endogenous-retroviruses-leading-to-autoimmune-diseases\/\" aria-label=\"Read more about Human endogenous retroviruses leading to autoimmune diseases\">Read more<\/a><\/div><\/li>\n<li><a class=\"wp-block-latest-posts__post-title\" href=\"https:\/\/inmuno.es\/index.php\/2026\/07\/24\/cure-for-psoriasis-a-prospective-outlook\/\">Cure for psoriasis &#8211; a prospective outlook<\/a><div class=\"wp-block-latest-posts__post-author\">by inmunoadmin<\/div><time datetime=\"2026-07-24T07:28:50+02:00\" class=\"wp-block-latest-posts__post-date\">24 de July de 2026<\/time><div class=\"wp-block-latest-posts__post-excerpt\">Curr Opin Immunol. 2026 Jul 23;102:102820. doi: 10.1016\/j.coi.2026.102820. Online ahead of print. ABSTRACT Once considered incurable, psoriasis is now being re-evaluated in light of sustained, drug-free remissions, prompting a redefinition of &#8216;cure&#8217; as long-term\/drug-free remission. Psoriatic disease is primarily driven by dysregulation of the interleukin-23 (IL-23)\/IL-17 axis, and the survival of tissue-resident memory T cells &#8230; <a title=\"Cure for psoriasis &#8211; a prospective outlook\" class=\"read-more\" href=\"https:\/\/inmuno.es\/index.php\/2026\/07\/24\/cure-for-psoriasis-a-prospective-outlook\/\" aria-label=\"Read more about Cure for psoriasis &#8211; a prospective outlook\">Read more<\/a><\/div><\/li>\n<li><a class=\"wp-block-latest-posts__post-title\" href=\"https:\/\/inmuno.es\/index.php\/2026\/07\/23\/calcium-signaling-in-microglial-immune-functions-current-understanding-and-implications-for-disease\/\">Calcium signaling in microglial immune functions: current understanding and implications for disease<\/a><div class=\"wp-block-latest-posts__post-author\">by inmunoadmin<\/div><time datetime=\"2026-07-23T01:22:02+02:00\" class=\"wp-block-latest-posts__post-date\">23 de July de 2026<\/time><div class=\"wp-block-latest-posts__post-excerpt\">Curr Opin Immunol. 2026 Jul 22;102:102819. doi: 10.1016\/j.coi.2026.102819. Online ahead of print. ABSTRACT Microglia are the resident innate immune cells of the brain that play essential roles in immune surveillance, phagocytosis, and neuroinflammatory responses. A central regulator of these diverse functions is intracellular Ca2+ signaling, which connects extracellular cues to transcriptional and metabolic programs that &#8230; <a title=\"Calcium signaling in microglial immune functions: current understanding and implications for disease\" class=\"read-more\" href=\"https:\/\/inmuno.es\/index.php\/2026\/07\/23\/calcium-signaling-in-microglial-immune-functions-current-understanding-and-implications-for-disease\/\" aria-label=\"Read more about Calcium signaling in microglial immune functions: current understanding and implications for disease\">Read more<\/a><\/div><\/li>\n<li><a class=\"wp-block-latest-posts__post-title\" href=\"https:\/\/inmuno.es\/index.php\/2026\/07\/21\/the-role-of-artificial-intelligence-in-clinical-trials-in-adult-and-pediatric-rheumatology\/\">The role of artificial intelligence in clinical trials in adult and pediatric rheumatology<\/a><div class=\"wp-block-latest-posts__post-author\">by inmunoadmin<\/div><time datetime=\"2026-07-21T00:32:05+02:00\" class=\"wp-block-latest-posts__post-date\">21 de July de 2026<\/time><div class=\"wp-block-latest-posts__post-excerpt\">Curr Opin Immunol. 2026 Jul 20;102:102818. doi: 10.1016\/j.coi.2026.102818. Online ahead of print. ABSTRACT The development of clinical trials is limited by high costs and methodological complexities. In this context, artificial intelligence (AI) is emerging as a key instrument for their optimization. In the early phases of study design and recruiting, generative AI systems may help &#8230; <a title=\"The role of artificial intelligence in clinical trials in adult and pediatric rheumatology\" class=\"read-more\" href=\"https:\/\/inmuno.es\/index.php\/2026\/07\/21\/the-role-of-artificial-intelligence-in-clinical-trials-in-adult-and-pediatric-rheumatology\/\" aria-label=\"Read more about The role of artificial intelligence in clinical trials in adult and pediatric rheumatology\">Read more<\/a><\/div><\/li>\n<li><a class=\"wp-block-latest-posts__post-title\" href=\"https:\/\/inmuno.es\/index.php\/2026\/07\/16\/gata2-deficiency-enhancer-deregulation-immune-surveillance-failure-and-clonal-evolution\/\">GATA2 deficiency: enhancer deregulation, immune surveillance failure, and clonal evolution<\/a><div class=\"wp-block-latest-posts__post-author\">by inmunoadmin<\/div><time datetime=\"2026-07-16T01:34:43+02:00\" class=\"wp-block-latest-posts__post-date\">16 de July de 2026<\/time><div class=\"wp-block-latest-posts__post-excerpt\">Curr Opin Immunol. 2026 Jul 15;102:102817. doi: 10.1016\/j.coi.2026.102817. Online ahead of print. ABSTRACT Germline mutations in GATA2 cause a syndromic inborn error of immunity characterized by cytopenia, infections, immune dysregulation, and a marked predisposition to myelodysplastic syndrome and acute myeloid leukemia. Initially defined by the DCML phenotype-dendritic cell, monocyte, B- and NK-cell deficiency-GATA2 deficiency is &#8230; <a title=\"GATA2 deficiency: enhancer deregulation, immune surveillance failure, and clonal evolution\" class=\"read-more\" href=\"https:\/\/inmuno.es\/index.php\/2026\/07\/16\/gata2-deficiency-enhancer-deregulation-immune-surveillance-failure-and-clonal-evolution\/\" aria-label=\"Read more about GATA2 deficiency: enhancer deregulation, immune surveillance failure, and clonal evolution\">Read more<\/a><\/div><\/li>\n<li><a class=\"wp-block-latest-posts__post-title\" href=\"https:\/\/inmuno.es\/index.php\/2026\/07\/11\/mapping-antibody-sequences-and-effector-functions-across-spatial-niches\/\">Mapping antibody sequences and effector functions across spatial niches<\/a><div class=\"wp-block-latest-posts__post-author\">by inmunoadmin<\/div><time datetime=\"2026-07-11T11:50:58+02:00\" class=\"wp-block-latest-posts__post-date\">11 de July de 2026<\/time><div class=\"wp-block-latest-posts__post-excerpt\">Curr Opin Immunol. 2026 Jul 10;102:102816. doi: 10.1016\/j.coi.2026.102816. Online ahead of print. ABSTRACT Antibodies are fundamental to human health but can also drive pathology. Each antibody has a molecular specificity, encoded by their clonally heritable B cell receptor (BCR). Recent advances in spatial transcriptomics coupled with repertoire sequencing have enabled capturing antibody-secreting cells (ASCs) and &#8230; <a title=\"Mapping antibody sequences and effector functions across spatial niches\" class=\"read-more\" href=\"https:\/\/inmuno.es\/index.php\/2026\/07\/11\/mapping-antibody-sequences-and-effector-functions-across-spatial-niches\/\" aria-label=\"Read more about Mapping antibody sequences and effector functions across spatial niches\">Read more<\/a><\/div><\/li>\n<li><a class=\"wp-block-latest-posts__post-title\" href=\"https:\/\/inmuno.es\/index.php\/2026\/07\/10\/the-epithelial-cell-in-sjogrens-syndrome-from-passive-target-to-orchestrator-of-autoimmune-reactivity\/\">The epithelial cell in Sj\u00f6gren&#8217;s syndrome: from passive target to orchestrator of autoimmune reactivity<\/a><div class=\"wp-block-latest-posts__post-author\">by inmunoadmin<\/div><time datetime=\"2026-07-10T07:25:59+02:00\" class=\"wp-block-latest-posts__post-date\">10 de July de 2026<\/time><div class=\"wp-block-latest-posts__post-excerpt\">Curr Opin Immunol. 2026 Jul 9;102:102815. doi: 10.1016\/j.coi.2026.102815. Online ahead of print. ABSTRACT Primary Sj\u00f6gren&#8217;s syndrome (pSS) is a systemic autoimmune disease characterized by sicca symptoms, fatigue, multiorgan involvement, and an increased risk of B-cell lymphoma. Accumulating evidence over the past decades indicates that epithelial cells are not passive targets but active drivers of disease. &#8230; <a title=\"The epithelial cell in Sj\u00f6gren&#8217;s syndrome: from passive target to orchestrator of autoimmune reactivity\" class=\"read-more\" href=\"https:\/\/inmuno.es\/index.php\/2026\/07\/10\/the-epithelial-cell-in-sjogrens-syndrome-from-passive-target-to-orchestrator-of-autoimmune-reactivity\/\" aria-label=\"Read more about The epithelial cell in Sj\u00f6gren&#8217;s syndrome: from passive target to orchestrator of autoimmune reactivity\">Read more<\/a><\/div><\/li>\n<li><a class=\"wp-block-latest-posts__post-title\" href=\"https:\/\/inmuno.es\/index.php\/2026\/07\/08\/the-food-additive-microbial-transglutaminase-is-a-potential-new-environmental-inducer-of-autoimmune-diseases\/\">The food additive microbial transglutaminase is a potential new environmental inducer of autoimmune diseases<\/a><div class=\"wp-block-latest-posts__post-author\">by inmunoadmin<\/div><time datetime=\"2026-07-08T01:44:11+02:00\" class=\"wp-block-latest-posts__post-date\">8 de July de 2026<\/time><div class=\"wp-block-latest-posts__post-excerpt\">Curr Opin Immunol. 2026 Jul 7;101:102812. doi: 10.1016\/j.coi.2026.102812. Online ahead of print. ABSTRACT Microbial transglutaminase (mTG) is a frequently used processed food additive, and the consumption of its cross-linked complexes is rapidly expanding. Despite numerous reports concerning its public safety, it is designated as a processing aid and classified as safe for use. mTG and\/or &#8230; <a title=\"The food additive microbial transglutaminase is a potential new environmental inducer of autoimmune diseases\" class=\"read-more\" href=\"https:\/\/inmuno.es\/index.php\/2026\/07\/08\/the-food-additive-microbial-transglutaminase-is-a-potential-new-environmental-inducer-of-autoimmune-diseases\/\" aria-label=\"Read more about The food additive microbial transglutaminase is a potential new environmental inducer of autoimmune diseases\">Read more<\/a><\/div><\/li>\n<li><a class=\"wp-block-latest-posts__post-title\" href=\"https:\/\/inmuno.es\/index.php\/2026\/07\/08\/mapping-the-synovial-immune-ecosystem-in-rheumatoid-arthritis-cellular-cartography-and-pathotype-guided-immune-restoration\/\">Mapping the synovial immune ecosystem in rheumatoid arthritis: cellular cartography and pathotype-guided immune restoration<\/a><div class=\"wp-block-latest-posts__post-author\">by inmunoadmin<\/div><time datetime=\"2026-07-08T01:44:11+02:00\" class=\"wp-block-latest-posts__post-date\">8 de July de 2026<\/time><div class=\"wp-block-latest-posts__post-excerpt\">Curr Opin Immunol. 2026 Jul 7;101:102811. doi: 10.1016\/j.coi.2026.102811. Online ahead of print. ABSTRACT Rheumatoid arthritis (RA) is not a uniform inflammatory pannus. It is a spatially organized, stage-dependent synovial immune ecosystem. Cellular cartography resolves synovitis into lymphoid, myeloid, stromal, and neuroimmune niches that track erosive disease, fibroproliferation, and pain-dominant states. Ecosystem state can differ between &#8230; <a title=\"Mapping the synovial immune ecosystem in rheumatoid arthritis: cellular cartography and pathotype-guided immune restoration\" class=\"read-more\" href=\"https:\/\/inmuno.es\/index.php\/2026\/07\/08\/mapping-the-synovial-immune-ecosystem-in-rheumatoid-arthritis-cellular-cartography-and-pathotype-guided-immune-restoration\/\" aria-label=\"Read more about Mapping the synovial immune ecosystem in rheumatoid arthritis: cellular cartography and pathotype-guided immune restoration\">Read more<\/a><\/div><\/li>\n<li><a class=\"wp-block-latest-posts__post-title\" href=\"https:\/\/inmuno.es\/index.php\/2026\/07\/07\/noncanonical-ion-channel-signaling-in-neurovascular-barrier-regulation-and-immune-cell-trafficking\/\">Noncanonical ion channel signaling in neurovascular barrier regulation and immune cell trafficking<\/a><div class=\"wp-block-latest-posts__post-author\">by inmunoadmin<\/div><time datetime=\"2026-07-07T01:23:27+02:00\" class=\"wp-block-latest-posts__post-date\">7 de July de 2026<\/time><div class=\"wp-block-latest-posts__post-excerpt\">Curr Opin Immunol. 2026 Jul 6;101:102813. doi: 10.1016\/j.coi.2026.102813. Online ahead of print. ABSTRACT Ion channels are classically regarded as regulators of electrical excitability, but their role in immune activation and barrier homeostasis extends far beyond global transmembrane ion flux. This functional diversity is, among other things, the result of noncanonical signaling pathways. In this review, &#8230; <a title=\"Noncanonical ion channel signaling in neurovascular barrier regulation and immune cell trafficking\" class=\"read-more\" href=\"https:\/\/inmuno.es\/index.php\/2026\/07\/07\/noncanonical-ion-channel-signaling-in-neurovascular-barrier-regulation-and-immune-cell-trafficking\/\" aria-label=\"Read more about Noncanonical ion channel signaling in neurovascular barrier regulation and immune cell trafficking\">Read more<\/a><\/div><\/li>\n<li><a class=\"wp-block-latest-posts__post-title\" href=\"https:\/\/inmuno.es\/index.php\/2026\/06\/30\/a-blind-spot-of-human-t-cell-immunology-epitope-specificity-in-secondary-lymphoid-organs\/\">A blind spot of human T cell immunology: epitope specificity in secondary lymphoid organs<\/a><div class=\"wp-block-latest-posts__post-author\">by inmunoadmin<\/div><time datetime=\"2026-06-30T01:00:34+02:00\" class=\"wp-block-latest-posts__post-date\">30 de June de 2026<\/time><div class=\"wp-block-latest-posts__post-excerpt\">Curr Opin Immunol. 2026 Jun 29;101:102809. doi: 10.1016\/j.coi.2026.102809. Online ahead of print. ABSTRACT The fate of T cells is determined through the expression of a unique T cell receptor (TCR). TCR epitope specificity drives spatial localization, phenotypic and metabolic plasticity, effector function, as well as the evolution of complex repertoires of T cell clones. However, &#8230; <a title=\"A blind spot of human T cell immunology: epitope specificity in secondary lymphoid organs\" class=\"read-more\" href=\"https:\/\/inmuno.es\/index.php\/2026\/06\/30\/a-blind-spot-of-human-t-cell-immunology-epitope-specificity-in-secondary-lymphoid-organs\/\" aria-label=\"Read more about A blind spot of human T cell immunology: epitope specificity in secondary lymphoid organs\">Read more<\/a><\/div><\/li>\n<li><a class=\"wp-block-latest-posts__post-title\" href=\"https:\/\/inmuno.es\/index.php\/2026\/06\/28\/germinal-center-responses-at-barrier-organ-sites\/\">Germinal center responses at barrier organ sites<\/a><div class=\"wp-block-latest-posts__post-author\">by inmunoadmin<\/div><time datetime=\"2026-06-28T01:03:24+02:00\" class=\"wp-block-latest-posts__post-date\">28 de June de 2026<\/time><div class=\"wp-block-latest-posts__post-excerpt\">Curr Opin Immunol. 2026 Jun 27;101:102807. doi: 10.1016\/j.coi.2026.102807. Online ahead of print. ABSTRACT In this review, we detail the features of barrier germinal centers (GC) that form in tertiary lymphoid structures (TLSs) within non-immune organs that host a local microbiome, and posit a framework of immunity where TLS-GCs created at barrier sites are a key &#8230; <a title=\"Germinal center responses at barrier organ sites\" class=\"read-more\" href=\"https:\/\/inmuno.es\/index.php\/2026\/06\/28\/germinal-center-responses-at-barrier-organ-sites\/\" aria-label=\"Read more about Germinal center responses at barrier organ sites\">Read more<\/a><\/div><\/li>\n<li><a class=\"wp-block-latest-posts__post-title\" href=\"https:\/\/inmuno.es\/index.php\/2026\/06\/28\/ocular-sarcoidosis-from-clinical-signs-to-targeted-interventions\/\">Ocular sarcoidosis: from clinical signs to targeted interventions<\/a><div class=\"wp-block-latest-posts__post-author\">by inmunoadmin<\/div><time datetime=\"2026-06-28T01:03:24+02:00\" class=\"wp-block-latest-posts__post-date\">28 de June de 2026<\/time><div class=\"wp-block-latest-posts__post-excerpt\">Curr Opin Immunol. 2026 Jun 27;101:102810. doi: 10.1016\/j.coi.2026.102810. Online ahead of print. ABSTRACT Ocular sarcoidosis is a frequent manifestation of sarcoidosis and may occur most commonly affecting adults between 30 and 60 years old. Uveitis may be anterior, intermediate, posterior, or present as panuveitis, with marked heterogeneity in severity and clinical course. Diagnosis relies on &#8230; <a title=\"Ocular sarcoidosis: from clinical signs to targeted interventions\" class=\"read-more\" href=\"https:\/\/inmuno.es\/index.php\/2026\/06\/28\/ocular-sarcoidosis-from-clinical-signs-to-targeted-interventions\/\" aria-label=\"Read more about Ocular sarcoidosis: from clinical signs to targeted interventions\">Read more<\/a><\/div><\/li>\n<li><a class=\"wp-block-latest-posts__post-title\" href=\"https:\/\/inmuno.es\/index.php\/2026\/06\/27\/on-or-within-spatial-determinants-of-antigen-handling-in-the-nasal-turbinates\/\">On or within: spatial determinants of antigen handling in the nasal turbinates<\/a><div class=\"wp-block-latest-posts__post-author\">by inmunoadmin<\/div><time datetime=\"2026-06-27T07:45:50+02:00\" class=\"wp-block-latest-posts__post-date\">27 de June de 2026<\/time><div class=\"wp-block-latest-posts__post-excerpt\">Curr Opin Immunol. 2026 Jun 26;101:102808. doi: 10.1016\/j.coi.2026.102808. Online ahead of print. ABSTRACT The SARS-CoV-2 pandemic has renewed interest in mucosal vaccines, yet these approaches have long struggled to generate durable protection against airway pathogens. A key limitation is the incomplete understanding of how upper airway antigens are handled to shape immune response quality and &#8230; <a title=\"On or within: spatial determinants of antigen handling in the nasal turbinates\" class=\"read-more\" href=\"https:\/\/inmuno.es\/index.php\/2026\/06\/27\/on-or-within-spatial-determinants-of-antigen-handling-in-the-nasal-turbinates\/\" aria-label=\"Read more about On or within: spatial determinants of antigen handling in the nasal turbinates\">Read more<\/a><\/div><\/li>\n<li><a class=\"wp-block-latest-posts__post-title\" href=\"https:\/\/inmuno.es\/index.php\/2026\/06\/24\/decoding-the-complexity-of-intestinal-immunity-with-spatial-transcriptomics\/\">Decoding the complexity of intestinal immunity with spatial transcriptomics<\/a><div class=\"wp-block-latest-posts__post-author\">by inmunoadmin<\/div><time datetime=\"2026-06-24T07:36:02+02:00\" class=\"wp-block-latest-posts__post-date\">24 de June de 2026<\/time><div class=\"wp-block-latest-posts__post-excerpt\">Curr Opin Immunol. 2026 Jun 23;101:102806. doi: 10.1016\/j.coi.2026.102806. Online ahead of print. ABSTRACT The intestine integrates nutrient digestion and absorption with immune surveillance, being continuously challenged by dietary antigens, commensal microbiota, and pathogens. Its highly regionalized structure requires the immune system to balance tolerance to food and commensal organisms with protective responses against pathogens, generating &#8230; <a title=\"Decoding the complexity of intestinal immunity with spatial transcriptomics\" class=\"read-more\" href=\"https:\/\/inmuno.es\/index.php\/2026\/06\/24\/decoding-the-complexity-of-intestinal-immunity-with-spatial-transcriptomics\/\" aria-label=\"Read more about Decoding the complexity of intestinal immunity with spatial transcriptomics\">Read more<\/a><\/div><\/li>\n<li><a class=\"wp-block-latest-posts__post-title\" href=\"https:\/\/inmuno.es\/index.php\/2026\/06\/23\/reconsidering-the-immunological-aspects-of-solid-phase-assays-for-antiphospholipid-antibodies-detection\/\">Reconsidering the immunological aspects of solid-phase assays for antiphospholipid antibodies detection<\/a><div class=\"wp-block-latest-posts__post-author\">by inmunoadmin<\/div><time datetime=\"2026-06-23T03:51:55+02:00\" class=\"wp-block-latest-posts__post-date\">23 de June de 2026<\/time><div class=\"wp-block-latest-posts__post-excerpt\">Curr Opin Immunol. 2026 Jun 22;101:102805. doi: 10.1016\/j.coi.2026.102805. Online ahead of print. ABSTRACT Solid\u2011phase assays for the detection of antiphospholipid antibodies (aPL) are central to the laboratory evaluation of antiphospholipid syndrome (APS). Growing insights into the molecular immunology underlying these assays challenge traditional interpretations. It is now evident that the antigenic drivers are phospholipids (PL)\u2011binding &#8230; <a title=\"Reconsidering the immunological aspects of solid-phase assays for antiphospholipid antibodies detection\" class=\"read-more\" href=\"https:\/\/inmuno.es\/index.php\/2026\/06\/23\/reconsidering-the-immunological-aspects-of-solid-phase-assays-for-antiphospholipid-antibodies-detection\/\" aria-label=\"Read more about Reconsidering the immunological aspects of solid-phase assays for antiphospholipid antibodies detection\">Read more<\/a><\/div><\/li>\n<li><a class=\"wp-block-latest-posts__post-title\" href=\"https:\/\/inmuno.es\/index.php\/2026\/06\/17\/engineering-human-synovial-organoids-as-predictive-ecosystems-for-disease-modeling-and-therapeutic-response-in-rheumatology\/\">Engineering human synovial organoids as predictive ecosystems for disease modeling and therapeutic response in rheumatology<\/a><div class=\"wp-block-latest-posts__post-author\">by inmunoadmin<\/div><time datetime=\"2026-06-17T06:58:39+02:00\" class=\"wp-block-latest-posts__post-date\">17 de June de 2026<\/time><div class=\"wp-block-latest-posts__post-excerpt\">Curr Opin Immunol. 2026 Jun 16;101:102793. doi: 10.1016\/j.coi.2026.102793. Online ahead of print. ABSTRACT The synovium is a critical site for the initiation and persistence of inflammatory joint diseases, including rheumatoid arthritis (RA), osteoarthritis (OA), and gout. Conventional 2D cultures and animal models fail to recapitulate the multicellular organization, mechanical regulation, and inter-tissue communication that shape &#8230; <a title=\"Engineering human synovial organoids as predictive ecosystems for disease modeling and therapeutic response in rheumatology\" class=\"read-more\" href=\"https:\/\/inmuno.es\/index.php\/2026\/06\/17\/engineering-human-synovial-organoids-as-predictive-ecosystems-for-disease-modeling-and-therapeutic-response-in-rheumatology\/\" aria-label=\"Read more about Engineering human synovial organoids as predictive ecosystems for disease modeling and therapeutic response in rheumatology\">Read more<\/a><\/div><\/li>\n<li><a class=\"wp-block-latest-posts__post-title\" href=\"https:\/\/inmuno.es\/index.php\/2026\/06\/16\/lymphatic-endothelial-cells-actively-shape-immune-responses-in-the-lungs\/\">Lymphatic endothelial cells actively shape immune responses in the lungs<\/a><div class=\"wp-block-latest-posts__post-author\">by inmunoadmin<\/div><time datetime=\"2026-06-16T07:23:15+02:00\" class=\"wp-block-latest-posts__post-date\">16 de June de 2026<\/time><div class=\"wp-block-latest-posts__post-excerpt\">Curr Opin Immunol. 2026 Jun 15;101:102802. doi: 10.1016\/j.coi.2026.102802. Online ahead of print. ABSTRACT Lymphatic vessels maintain fluid balance and immune protection by transporting fluid, solutes and cells from tissue interstitial spaces to lymph nodes. The lymphatic endothelial cells that form lymphatics differentiate throughout the body to fulfil organ-specific roles. In the lungs, specialised pulmonary lymphatic &#8230; <a title=\"Lymphatic endothelial cells actively shape immune responses in the lungs\" class=\"read-more\" href=\"https:\/\/inmuno.es\/index.php\/2026\/06\/16\/lymphatic-endothelial-cells-actively-shape-immune-responses-in-the-lungs\/\" aria-label=\"Read more about Lymphatic endothelial cells actively shape immune responses in the lungs\">Read more<\/a><\/div><\/li>\n<li><a class=\"wp-block-latest-posts__post-title\" href=\"https:\/\/inmuno.es\/index.php\/2026\/06\/15\/raynauds-phenomenon-a-vascular-or-an-autoimmune-mediated-disorder-facts-and-fancy\/\">Raynaud&#8217;s phenomenon: a vascular or an autoimmune-mediated disorder? Facts and fancy<\/a><div class=\"wp-block-latest-posts__post-author\">by inmunoadmin<\/div><time datetime=\"2026-06-15T18:04:00+02:00\" class=\"wp-block-latest-posts__post-date\">15 de June de 2026<\/time><div class=\"wp-block-latest-posts__post-excerpt\">Curr Opin Immunol. 2026 Jun 13;101:102803. doi: 10.1016\/j.coi.2026.102803. Online ahead of print. ABSTRACT Raynaud&#8217;s phenomenon (RP) is a common vasospastic disorder characterized by transient digital ischemia triggered by cold exposure or emotional stress. It is classified as primary or secondary, the latter often associated with autoimmune connective tissue diseases such as systemic sclerosis, mixed connective &#8230; <a title=\"Raynaud&#8217;s phenomenon: a vascular or an autoimmune-mediated disorder? Facts and fancy\" class=\"read-more\" href=\"https:\/\/inmuno.es\/index.php\/2026\/06\/15\/raynauds-phenomenon-a-vascular-or-an-autoimmune-mediated-disorder-facts-and-fancy\/\" aria-label=\"Read more about Raynaud&#8217;s phenomenon: a vascular or an autoimmune-mediated disorder? Facts and fancy\">Read more<\/a><\/div><\/li>\n<li><a class=\"wp-block-latest-posts__post-title\" href=\"https:\/\/inmuno.es\/index.php\/2026\/06\/05\/hantavirus-on-the-rise-clinical-virological-immunological-and-public-health-perspectives\/\">Hantavirus on the rise: clinical, virological, immunological, and public health perspectives<\/a><div class=\"wp-block-latest-posts__post-author\">by inmunoadmin<\/div><time datetime=\"2026-06-05T06:52:13+02:00\" class=\"wp-block-latest-posts__post-date\">5 de June de 2026<\/time><div class=\"wp-block-latest-posts__post-excerpt\">Curr Opin Immunol. 2026 Jun 4;101:102804. doi: 10.1016\/j.coi.2026.102804. Online ahead of print. ABSTRACT Hantaviruses are enveloped, negative-sense RNA viruses. Rodents serve as natural reservoirs, and spillover into humans causes hemorrhagic fever with renal syndrome and hantavirus pulmonary syndrome. While transmission typically occurs by inhaling aerosolized rodent excreta, the Andes virus variant is capable of human-to-human &#8230; <a title=\"Hantavirus on the rise: clinical, virological, immunological, and public health perspectives\" class=\"read-more\" href=\"https:\/\/inmuno.es\/index.php\/2026\/06\/05\/hantavirus-on-the-rise-clinical-virological-immunological-and-public-health-perspectives\/\" aria-label=\"Read more about Hantavirus on the rise: clinical, virological, immunological, and public health perspectives\">Read more<\/a><\/div><\/li>\n<li><a class=\"wp-block-latest-posts__post-title\" href=\"https:\/\/inmuno.es\/index.php\/2026\/06\/03\/spatial-omics-of-immunity-mapping-cellular-landscapes-in-tissue-microenvironments\/\">Spatial omics of immunity: Mapping cellular landscapes in tissue microenvironments<\/a><div class=\"wp-block-latest-posts__post-author\">by inmunoadmin<\/div><time datetime=\"2026-06-03T06:45:23+02:00\" class=\"wp-block-latest-posts__post-date\">3 de June de 2026<\/time><div class=\"wp-block-latest-posts__post-excerpt\">Curr Opin Immunol. 2026 Jun 2;101:102790. doi: 10.1016\/j.coi.2026.102790. Online ahead of print. ABSTRACT The tumor microenvironment (TME) is composed of diverse heterogeneous components and plays a crucial role in immune cell infiltration, immune evasion, and dynamic interactions between tumor cells and the immune system. A precise understanding of the TME is essential for tissue immunology &#8230; <a title=\"Spatial omics of immunity: Mapping cellular landscapes in tissue microenvironments\" class=\"read-more\" href=\"https:\/\/inmuno.es\/index.php\/2026\/06\/03\/spatial-omics-of-immunity-mapping-cellular-landscapes-in-tissue-microenvironments\/\" aria-label=\"Read more about Spatial omics of immunity: Mapping cellular landscapes in tissue microenvironments\">Read more<\/a><\/div><\/li>\n<li><a class=\"wp-block-latest-posts__post-title\" href=\"https:\/\/inmuno.es\/index.php\/2026\/05\/30\/novel-mechanisms-linking-platelet-activation-to-antiphospholipid-syndrome\/\">Novel mechanisms linking platelet activation to antiphospholipid syndrome<\/a><div class=\"wp-block-latest-posts__post-author\">by inmunoadmin<\/div><time datetime=\"2026-05-30T07:14:16+02:00\" class=\"wp-block-latest-posts__post-date\">30 de May de 2026<\/time><div class=\"wp-block-latest-posts__post-excerpt\">Curr Opin Immunol. 2026 May 29;101:102791. doi: 10.1016\/j.coi.2026.102791. Online ahead of print. ABSTRACT Antiphospholipid syndrome (APS) is a thromboinflammatory disorder in which antiphospholipid antibodies (aPL), particularly anti-\u03b22GPI, initiate a complex, graded platelet activation that integrates immune signaling with coagulation. Clinical and multiparametric flow-cytometric evidence demonstrates a sustained prothrombotic platelet endotype characterized by enrichment of tissue &#8230; <a title=\"Novel mechanisms linking platelet activation to antiphospholipid syndrome\" class=\"read-more\" href=\"https:\/\/inmuno.es\/index.php\/2026\/05\/30\/novel-mechanisms-linking-platelet-activation-to-antiphospholipid-syndrome\/\" aria-label=\"Read more about Novel mechanisms linking platelet activation to antiphospholipid syndrome\">Read more<\/a><\/div><\/li>\n<li><a class=\"wp-block-latest-posts__post-title\" href=\"https:\/\/inmuno.es\/index.php\/2026\/05\/28\/when-the-lung-is-at-risk-diagnosis-manifestations-and-complications-of-pulmonary-sarcoidosis\/\">When the lung is at risk: diagnosis, manifestations, and complications of pulmonary sarcoidosis<\/a><div class=\"wp-block-latest-posts__post-author\">by inmunoadmin<\/div><time datetime=\"2026-05-28T06:27:57+02:00\" class=\"wp-block-latest-posts__post-date\">28 de May de 2026<\/time><div class=\"wp-block-latest-posts__post-excerpt\">Curr Opin Immunol. 2026 May 27;101:102792. doi: 10.1016\/j.coi.2026.102792. Online ahead of print. ABSTRACT Sarcoidosis is a heterogeneous granulomatous disease of unknown origin; a subset of patients develops an advanced pulmonary disease phenotype, marked by progressive pulmonary fibrosis, airway involvement, and sarcoidosis-associated pulmonary hypertension, leading to high morbidity and mortality. In this review, we summarize key &#8230; <a title=\"When the lung is at risk: diagnosis, manifestations, and complications of pulmonary sarcoidosis\" class=\"read-more\" href=\"https:\/\/inmuno.es\/index.php\/2026\/05\/28\/when-the-lung-is-at-risk-diagnosis-manifestations-and-complications-of-pulmonary-sarcoidosis\/\" aria-label=\"Read more about When the lung is at risk: diagnosis, manifestations, and complications of pulmonary sarcoidosis\">Read more<\/a><\/div><\/li>\n<li><a class=\"wp-block-latest-posts__post-title\" href=\"https:\/\/inmuno.es\/index.php\/2026\/05\/24\/biochemical-and-cytokine-environment-in-skeletally-immature-patients-after-traumatic-knee-injuries\/\">Biochemical and cytokine environment in skeletally immature patients after traumatic knee injuries<\/a><div class=\"wp-block-latest-posts__post-author\">by inmunoadmin<\/div><time datetime=\"2026-05-24T10:45:50+02:00\" class=\"wp-block-latest-posts__post-date\">24 de May de 2026<\/time><div class=\"wp-block-latest-posts__post-excerpt\">Curr Opin Immunol. 2026 May 23;101:102789. doi: 10.1016\/j.coi.2026.102789. Online ahead of print. ABSTRACT Traumatic knee injuries in skeletally immature patients occur in a unique biological context shaped by growth, high tissue turnover, and distinct immune-repair dynamics. Beyond structural damage, acute post-traumatic changes in synovial fluid and cartilage metabolism can set the trajectory toward persistent symptoms &#8230; <a title=\"Biochemical and cytokine environment in skeletally immature patients after traumatic knee injuries\" class=\"read-more\" href=\"https:\/\/inmuno.es\/index.php\/2026\/05\/24\/biochemical-and-cytokine-environment-in-skeletally-immature-patients-after-traumatic-knee-injuries\/\" aria-label=\"Read more about Biochemical and cytokine environment in skeletally immature patients after traumatic knee injuries\">Read more<\/a><\/div><\/li>\n<li><a class=\"wp-block-latest-posts__post-title\" href=\"https:\/\/inmuno.es\/index.php\/2026\/05\/22\/new-learnings-from-the-molecular-pathology-of-the-synovial-tissue-in-rheumatoid-arthritis-from-pathogenesis-to-therapeutic-targeting-toward-precision-medicine\/\">New learnings from the molecular pathology of the synovial tissue in rheumatoid arthritis: from pathogenesis to therapeutic targeting toward precision medicine<\/a><div class=\"wp-block-latest-posts__post-author\">by inmunoadmin<\/div><time datetime=\"2026-05-22T07:30:53+02:00\" class=\"wp-block-latest-posts__post-date\">22 de May de 2026<\/time><div class=\"wp-block-latest-posts__post-excerpt\">Curr Opin Immunol. 2026 May 21;101:102785. doi: 10.1016\/j.coi.2026.102785. Online ahead of print. ABSTRACT Despite the success of targeted therapies in rheumatoid arthritis, the lack of predictive biomarkers of response leads to an empirical treatment approach, often delaying effective intervention due to non-response to the initially selected individualized medication regimens in approximately 40% of patients. Cellular &#8230; <a title=\"New learnings from the molecular pathology of the synovial tissue in rheumatoid arthritis: from pathogenesis to therapeutic targeting toward precision medicine\" class=\"read-more\" href=\"https:\/\/inmuno.es\/index.php\/2026\/05\/22\/new-learnings-from-the-molecular-pathology-of-the-synovial-tissue-in-rheumatoid-arthritis-from-pathogenesis-to-therapeutic-targeting-toward-precision-medicine\/\" aria-label=\"Read more about New learnings from the molecular pathology of the synovial tissue in rheumatoid arthritis: from pathogenesis to therapeutic targeting toward precision medicine\">Read more<\/a><\/div><\/li>\n<li><a class=\"wp-block-latest-posts__post-title\" href=\"https:\/\/inmuno.es\/index.php\/2026\/05\/16\/dendritic-cell-homeostasis-in-the-splenic-microenvironment\/\">Dendritic cell homeostasis in the splenic microenvironment<\/a><div class=\"wp-block-latest-posts__post-author\">by inmunoadmin<\/div><time datetime=\"2026-05-16T06:52:16+02:00\" class=\"wp-block-latest-posts__post-date\">16 de May de 2026<\/time><div class=\"wp-block-latest-posts__post-excerpt\">Curr Opin Immunol. 2026 May 15;101:102788. doi: 10.1016\/j.coi.2026.102788. Online ahead of print. ABSTRACT The spleen is a central immune organ that surveys blood-borne pathogens and coordinates systemic immune responses. Within this organ, conventional dendritic cell (cDC) subsets occupy blood-exposed niches that enable efficient antigen capture and rapid initiation of T cell activation. While splenic cDC1s &#8230; <a title=\"Dendritic cell homeostasis in the splenic microenvironment\" class=\"read-more\" href=\"https:\/\/inmuno.es\/index.php\/2026\/05\/16\/dendritic-cell-homeostasis-in-the-splenic-microenvironment\/\" aria-label=\"Read more about Dendritic cell homeostasis in the splenic microenvironment\">Read more<\/a><\/div><\/li>\n<li><a class=\"wp-block-latest-posts__post-title\" href=\"https:\/\/inmuno.es\/index.php\/2026\/05\/15\/can-we-cure-primary-biliary-cholangitis\/\">Can we cure primary biliary cholangitis?<\/a><div class=\"wp-block-latest-posts__post-author\">by inmunoadmin<\/div><time datetime=\"2026-05-15T01:23:21+02:00\" class=\"wp-block-latest-posts__post-date\">15 de May de 2026<\/time><div class=\"wp-block-latest-posts__post-excerpt\">Curr Opin Immunol. 2026 May 14;100:102786. doi: 10.1016\/j.coi.2026.102786. Online ahead of print. ABSTRACT Primary biliary cholangitis (PBC) is a chronic immune-mediated liver disease characterized by progressive destruction of the intrahepatic bile ducts, leading to cholestasis, fibrosis, and eventual cirrhosis. Despite advances in understanding disease pathogenesis, treatment pathways are focused on maintenance rather than cure. Moreover, &#8230; <a title=\"Can we cure primary biliary cholangitis?\" class=\"read-more\" href=\"https:\/\/inmuno.es\/index.php\/2026\/05\/15\/can-we-cure-primary-biliary-cholangitis\/\" aria-label=\"Read more about Can we cure primary biliary cholangitis?\">Read more<\/a><\/div><\/li>\n<li><a class=\"wp-block-latest-posts__post-title\" href=\"https:\/\/inmuno.es\/index.php\/2026\/05\/15\/wont-you-be-my-neighbor-control-of-the-immune-response-by-stromal-and-immune-cell-microenvironments-within-the-lymph-node\/\">Won&#8217;t you be my neighbor? Control of the immune response by stromal and immune cell microenvironments within the lymph node<\/a><div class=\"wp-block-latest-posts__post-author\">by inmunoadmin<\/div><time datetime=\"2026-05-15T01:23:21+02:00\" class=\"wp-block-latest-posts__post-date\">15 de May de 2026<\/time><div class=\"wp-block-latest-posts__post-excerpt\">Curr Opin Immunol. 2026 May 13;100:102787. doi: 10.1016\/j.coi.2026.102787. Online ahead of print. ABSTRACT Efficacious immune responses require the coordinated encounter of rare antigen-specific adaptive lymphocytes with their cognate innate antigen-presenting cells (APCs) in space and time. This spatiotemporal problem of immunity is solved by secondary lymphoid organs, such as lymph nodes (LNs), which coordinate adaptive &#8230; <a title=\"Won&#8217;t you be my neighbor? Control of the immune response by stromal and immune cell microenvironments within the lymph node\" class=\"read-more\" href=\"https:\/\/inmuno.es\/index.php\/2026\/05\/15\/wont-you-be-my-neighbor-control-of-the-immune-response-by-stromal-and-immune-cell-microenvironments-within-the-lymph-node\/\" aria-label=\"Read more about Won&#8217;t you be my neighbor? Control of the immune response by stromal and immune cell microenvironments within the lymph node\">Read more<\/a><\/div><\/li>\n<li><a class=\"wp-block-latest-posts__post-title\" href=\"https:\/\/inmuno.es\/index.php\/2026\/05\/06\/the-role-of-different-apl-subpopulations-in-the-lupus-anticoagulant-phenomenon\/\">The role of different aPL subpopulations in the lupus anticoagulant phenomenon<\/a><div class=\"wp-block-latest-posts__post-author\">by inmunoadmin<\/div><time datetime=\"2026-05-06T07:30:56+02:00\" class=\"wp-block-latest-posts__post-date\">6 de May de 2026<\/time><div class=\"wp-block-latest-posts__post-excerpt\">Curr Opin Immunol. 2026 May 4;100:102784. doi: 10.1016\/j.coi.2026.102784. Online ahead of print. ABSTRACT The lupus anticoagulant (LA) phenomenon represents a paradoxical prothrombotic state characterised by inhibition of phospholipid-dependent coagulation assays in vitro, despite a strong association with thrombosis and pregnancy morbidity in vivo. LA is a central laboratory criterion for the diagnosis and risk stratification &#8230; <a title=\"The role of different aPL subpopulations in the lupus anticoagulant phenomenon\" class=\"read-more\" href=\"https:\/\/inmuno.es\/index.php\/2026\/05\/06\/the-role-of-different-apl-subpopulations-in-the-lupus-anticoagulant-phenomenon\/\" aria-label=\"Read more about The role of different aPL subpopulations in the lupus anticoagulant phenomenon\">Read more<\/a><\/div><\/li>\n<li><a class=\"wp-block-latest-posts__post-title\" href=\"https:\/\/inmuno.es\/index.php\/2026\/05\/02\/outcome-measures-in-systemic-lupus-erythematosus\/\">Outcome measures in systemic lupus erythematosus<\/a><div class=\"wp-block-latest-posts__post-author\">by inmunoadmin<\/div><time datetime=\"2026-05-02T06:53:47+02:00\" class=\"wp-block-latest-posts__post-date\">2 de May de 2026<\/time><div class=\"wp-block-latest-posts__post-excerpt\">Curr Opin Immunol. 2026 Apr 30;100:102782. doi: 10.1016\/j.coi.2026.102782. Online ahead of print. ABSTRACT Systemic lupus erythematosus (SLE) is a heterogeneous autoimmune disease characterized by fluctuating multisystem involvement, relapsing-remitting activity, and substantial risk of irreversible organ damage. Standardized disease activity indices have facilitated clinical trials and research, yet integration into clinical practice has not occurred for &#8230; <a title=\"Outcome measures in systemic lupus erythematosus\" class=\"read-more\" href=\"https:\/\/inmuno.es\/index.php\/2026\/05\/02\/outcome-measures-in-systemic-lupus-erythematosus\/\" aria-label=\"Read more about Outcome measures in systemic lupus erythematosus\">Read more<\/a><\/div><\/li>\n<li><a class=\"wp-block-latest-posts__post-title\" href=\"https:\/\/inmuno.es\/index.php\/2026\/05\/01\/optimal-donor-selection-for-transplant-to-reduce-gvhd-risk-and-augment-graft-versus-malignancy-efficacy\/\">Optimal donor selection for transplant to reduce GVHD risk and augment graft-versus-malignancy efficacy<\/a><div class=\"wp-block-latest-posts__post-author\">by inmunoadmin<\/div><time datetime=\"2026-05-01T07:24:02+02:00\" class=\"wp-block-latest-posts__post-date\">1 de May de 2026<\/time><div class=\"wp-block-latest-posts__post-excerpt\">Curr Opin Immunol. 2026 Apr 29;100:102783. doi: 10.1016\/j.coi.2026.102783. Online ahead of print. ABSTRACT Allogeneic hematopoietic cell transplantation (alloHCT) is curative for many patients with high-risk, hematologic malignancies. AlloHCT depends on a graft versus malignancy (GVM) phenomenon, whereby donor-derived immune cells recognize and eradicate malignant host cells. Successful GVM correlates with the risk of alloreactivity against &#8230; <a title=\"Optimal donor selection for transplant to reduce GVHD risk and augment graft-versus-malignancy efficacy\" class=\"read-more\" href=\"https:\/\/inmuno.es\/index.php\/2026\/05\/01\/optimal-donor-selection-for-transplant-to-reduce-gvhd-risk-and-augment-graft-versus-malignancy-efficacy\/\" aria-label=\"Read more about Optimal donor selection for transplant to reduce GVHD risk and augment graft-versus-malignancy efficacy\">Read more<\/a><\/div><\/li>\n<li><a class=\"wp-block-latest-posts__post-title\" href=\"https:\/\/inmuno.es\/index.php\/2026\/04\/29\/from-sensing-to-shaping-microglial-responses-in-the-pathogenesis-of-viral-encephalitis\/\">From sensing to shaping: microglial responses in the pathogenesis of viral encephalitis<\/a><div class=\"wp-block-latest-posts__post-author\">by inmunoadmin<\/div><time datetime=\"2026-04-29T06:36:28+02:00\" class=\"wp-block-latest-posts__post-date\">29 de April de 2026<\/time><div class=\"wp-block-latest-posts__post-excerpt\">Curr Opin Immunol. 2026 Apr 27;100:102781. doi: 10.1016\/j.coi.2026.102781. Online ahead of print. ABSTRACT Viral encephalitis (VE) is a universal menace accounting for severe morbidity and mortality among the affected individuals. VE is the cerebral inflammation triggered by viral infections. In the central nervous system, microglia are the frontline responders that provide defense against invading pathogens, &#8230; <a title=\"From sensing to shaping: microglial responses in the pathogenesis of viral encephalitis\" class=\"read-more\" href=\"https:\/\/inmuno.es\/index.php\/2026\/04\/29\/from-sensing-to-shaping-microglial-responses-in-the-pathogenesis-of-viral-encephalitis\/\" aria-label=\"Read more about From sensing to shaping: microglial responses in the pathogenesis of viral encephalitis\">Read more<\/a><\/div><\/li>\n<li><a class=\"wp-block-latest-posts__post-title\" href=\"https:\/\/inmuno.es\/index.php\/2026\/04\/24\/crac-channels-as-targets-for-immunotherapy\/\">CRAC channels as targets for immunotherapy<\/a><div class=\"wp-block-latest-posts__post-author\">by inmunoadmin<\/div><time datetime=\"2026-04-24T06:52:55+02:00\" class=\"wp-block-latest-posts__post-date\">24 de April de 2026<\/time><div class=\"wp-block-latest-posts__post-excerpt\">Curr Opin Immunol. 2026 Apr 22;100:102780. doi: 10.1016\/j.coi.2026.102780. Online ahead of print. ABSTRACT Ca\u00b2\u207a release-activated Ca\u00b2\u207a (CRAC) channels facilitate store-operated Ca\u00b2\u207a entry in both immune and nonimmune cells. They are crucial for the function of many immune cell types and strongly associated with the pathophysiology of immune-related disorders. Inherited null mutations in the genes encoding &#8230; <a title=\"CRAC channels as targets for immunotherapy\" class=\"read-more\" href=\"https:\/\/inmuno.es\/index.php\/2026\/04\/24\/crac-channels-as-targets-for-immunotherapy\/\" aria-label=\"Read more about CRAC channels as targets for immunotherapy\">Read more<\/a><\/div><\/li>\n<li><a class=\"wp-block-latest-posts__post-title\" href=\"https:\/\/inmuno.es\/index.php\/2026\/04\/22\/understanding-antiphospholipid-syndrome-clinical-phenotypes-with-the-guidance-of-antiphospholipid-antibody-related-pathogenic-mechanisms\/\">Understanding antiphospholipid syndrome clinical phenotypes with the guidance of antiphospholipid antibody-related pathogenic mechanisms<\/a><div class=\"wp-block-latest-posts__post-author\">by inmunoadmin<\/div><time datetime=\"2026-04-22T00:51:15+02:00\" class=\"wp-block-latest-posts__post-date\">22 de April de 2026<\/time><div class=\"wp-block-latest-posts__post-excerpt\">Curr Opin Immunol. 2026 Apr 20;100:102770. doi: 10.1016\/j.coi.2026.102770. Online ahead of print. ABSTRACT Antiphospholipid syndrome (APS) is a systemic autoimmune disorder characterized by thrombosis, microvascular disease, pregnancy morbidity, or non-thrombotic manifestations in patients with antiphospholipid antibodies. The mechanistic differentiation of these clinical phenotypes has diagnostic and therapeutic implications. Across APS phenotypes, a shared set of &#8230; <a title=\"Understanding antiphospholipid syndrome clinical phenotypes with the guidance of antiphospholipid antibody-related pathogenic mechanisms\" class=\"read-more\" href=\"https:\/\/inmuno.es\/index.php\/2026\/04\/22\/understanding-antiphospholipid-syndrome-clinical-phenotypes-with-the-guidance-of-antiphospholipid-antibody-related-pathogenic-mechanisms\/\" aria-label=\"Read more about Understanding antiphospholipid syndrome clinical phenotypes with the guidance of antiphospholipid antibody-related pathogenic mechanisms\">Read more<\/a><\/div><\/li>\n<li><a class=\"wp-block-latest-posts__post-title\" href=\"https:\/\/inmuno.es\/index.php\/2026\/04\/19\/immunosenescence-and-human-healthspan-lessons-from-centenarians\/\">Immunosenescence and human healthspan. Lessons from centenarians<\/a><div class=\"wp-block-latest-posts__post-author\">by inmunoadmin<\/div><time datetime=\"2026-04-19T19:08:15+02:00\" class=\"wp-block-latest-posts__post-date\">19 de April de 2026<\/time><div class=\"wp-block-latest-posts__post-excerpt\">Curr Opin Immunol. 2026 Apr 16;100:102777. doi: 10.1016\/j.coi.2026.102777. Online ahead of print. ABSTRACT Immunosenescence is a multidimensional remodeling of immunity, characterized by inflammaging, cellular senescence, T-cell exhaustion, and thymic involution, that raises infection and disease risk with age. Emerging evidence, notably from centenarians, shows immune aging follows divergent trajectories: rather than a uniform decline, extreme &#8230; <a title=\"Immunosenescence and human healthspan. Lessons from centenarians\" class=\"read-more\" href=\"https:\/\/inmuno.es\/index.php\/2026\/04\/19\/immunosenescence-and-human-healthspan-lessons-from-centenarians\/\" aria-label=\"Read more about Immunosenescence and human healthspan. Lessons from centenarians\">Read more<\/a><\/div><\/li>\n<li><a class=\"wp-block-latest-posts__post-title\" href=\"https:\/\/inmuno.es\/index.php\/2026\/04\/19\/a-critical-look-at-disease-classification-diagnosis-criteria-in-rheumatology\/\">A critical look at disease classification\/diagnosis criteria in rheumatology<\/a><div class=\"wp-block-latest-posts__post-author\">by inmunoadmin<\/div><time datetime=\"2026-04-19T19:08:15+02:00\" class=\"wp-block-latest-posts__post-date\">19 de April de 2026<\/time><div class=\"wp-block-latest-posts__post-excerpt\">Curr Opin Immunol. 2026 Apr 16;100:102779. doi: 10.1016\/j.coi.2026.102779. Online ahead of print. ABSTRACT Multiple sets of classification\/diagnostic criteria have been revised recently in rheumatology, with issues from why to how they were developed coming to light. These issues range from the worse specificity of the new sets of criteria to methodological issues in their development, &#8230; <a title=\"A critical look at disease classification\/diagnosis criteria in rheumatology\" class=\"read-more\" href=\"https:\/\/inmuno.es\/index.php\/2026\/04\/19\/a-critical-look-at-disease-classification-diagnosis-criteria-in-rheumatology\/\" aria-label=\"Read more about A critical look at disease classification\/diagnosis criteria in rheumatology\">Read more<\/a><\/div><\/li>\n<li><a class=\"wp-block-latest-posts__post-title\" href=\"https:\/\/inmuno.es\/index.php\/2026\/04\/19\/a-critical-look-at-observational-studies\/\">A critical look at observational studies<\/a><div class=\"wp-block-latest-posts__post-author\">by inmunoadmin<\/div><time datetime=\"2026-04-19T19:08:15+02:00\" class=\"wp-block-latest-posts__post-date\">19 de April de 2026<\/time><div class=\"wp-block-latest-posts__post-excerpt\">Curr Opin Immunol. 2026 Apr 16;100:102778. doi: 10.1016\/j.coi.2026.102778. Online ahead of print. ABSTRACT Observational studies serve as a critical alternative when randomized trials are precluded by ethical concerns, high costs, or the need for rapid evidence-based hypothesis generation. Increasing reliance on routinely collected observational data (electronic health records, registries, and claims) has been accompanied by &#8230; <a title=\"A critical look at observational studies\" class=\"read-more\" href=\"https:\/\/inmuno.es\/index.php\/2026\/04\/19\/a-critical-look-at-observational-studies\/\" aria-label=\"Read more about A critical look at observational studies\">Read more<\/a><\/div><\/li>\n<li><a class=\"wp-block-latest-posts__post-title\" href=\"https:\/\/inmuno.es\/index.php\/2026\/04\/17\/hot-topics-in-the-antiphospholipid-syndrome\/\">Hot topics in the antiphospholipid syndrome<\/a><div class=\"wp-block-latest-posts__post-author\">by inmunoadmin<\/div><time datetime=\"2026-04-17T19:28:32+02:00\" class=\"wp-block-latest-posts__post-date\">17 de April de 2026<\/time><div class=\"wp-block-latest-posts__post-excerpt\">Curr Opin Immunol. 2026 Apr 15;100:102775. doi: 10.1016\/j.coi.2026.102775. Online ahead of print. ABSTRACT Antiphospholipid syndrome (APS) presents ongoing challenges in understanding its pathogenesis, standardizing diagnostic tests, and optimizing treatment strategies. The 18th International Congress on Antiphospholipid Antibodies (ICAPA) was held in Kyoto in September 2025. This narrative meeting wrap-up summarizes selected highlights from the Congress &#8230; <a title=\"Hot topics in the antiphospholipid syndrome\" class=\"read-more\" href=\"https:\/\/inmuno.es\/index.php\/2026\/04\/17\/hot-topics-in-the-antiphospholipid-syndrome\/\" aria-label=\"Read more about Hot topics in the antiphospholipid syndrome\">Read more<\/a><\/div><\/li>\n<li><a class=\"wp-block-latest-posts__post-title\" href=\"https:\/\/inmuno.es\/index.php\/2026\/04\/16\/new-developments-and-future-directions-in-the-management-of-systemic-lupus-erythematosus\/\">New developments and future directions in the management of systemic lupus erythematosus<\/a><div class=\"wp-block-latest-posts__post-author\">by inmunoadmin<\/div><time datetime=\"2026-04-16T00:53:18+02:00\" class=\"wp-block-latest-posts__post-date\">16 de April de 2026<\/time><div class=\"wp-block-latest-posts__post-excerpt\">Curr Opin Immunol. 2026 Apr 14;100:102774. doi: 10.1016\/j.coi.2026.102774. Online ahead of print. ABSTRACT Systemic lupus erythematosus (SLE) is a systemic autoimmune disorder with a pathogenesis that includes aberrant interactions between the innate and adaptive immune systems. Dominant pathogenetic axes include the type I interferon pathway and loss of tolerance in B cell\/plasma cell development with &#8230; <a title=\"New developments and future directions in the management of systemic lupus erythematosus\" class=\"read-more\" href=\"https:\/\/inmuno.es\/index.php\/2026\/04\/16\/new-developments-and-future-directions-in-the-management-of-systemic-lupus-erythematosus\/\" aria-label=\"Read more about New developments and future directions in the management of systemic lupus erythematosus\">Read more<\/a><\/div><\/li>\n<li><a class=\"wp-block-latest-posts__post-title\" href=\"https:\/\/inmuno.es\/index.php\/2026\/04\/15\/a-global-perspective-on-autoimmunity-and-immunodeficiency-exploring-geoepidemiology-trends\/\">A global perspective on autoimmunity and immunodeficiency: exploring geoepidemiology trends<\/a><div class=\"wp-block-latest-posts__post-author\">by inmunoadmin<\/div><time datetime=\"2026-04-15T06:37:53+02:00\" class=\"wp-block-latest-posts__post-date\">15 de April de 2026<\/time><div class=\"wp-block-latest-posts__post-excerpt\">Curr Opin Immunol. 2026 Apr 13;100:102773. doi: 10.1016\/j.coi.2026.102773. Online ahead of print. ABSTRACT Autoimmune and primary immunodeficiency disorders represent a growing global health burden influenced by a complex interplay of genetic, environmental, and socioeconomic factors. This paper offers a geoepidemiological analysis of these conditions, highlighting regional differences in incidence, diagnosis, and outcomes. Immunodeficiencies such as &#8230; <a title=\"A global perspective on autoimmunity and immunodeficiency: exploring geoepidemiology trends\" class=\"read-more\" href=\"https:\/\/inmuno.es\/index.php\/2026\/04\/15\/a-global-perspective-on-autoimmunity-and-immunodeficiency-exploring-geoepidemiology-trends\/\" aria-label=\"Read more about A global perspective on autoimmunity and immunodeficiency: exploring geoepidemiology trends\">Read more<\/a><\/div><\/li>\n<li><a class=\"wp-block-latest-posts__post-title\" href=\"https:\/\/inmuno.es\/index.php\/2026\/04\/10\/why-we-need-to-maintain-a-critical-view-on-big-data-and-artificial-intelligence-predictions\/\">Why we need to maintain a critical view on big data and artificial intelligence predictions<\/a><div class=\"wp-block-latest-posts__post-author\">by inmunoadmin<\/div><time datetime=\"2026-04-10T06:53:00+02:00\" class=\"wp-block-latest-posts__post-date\">10 de April de 2026<\/time><div class=\"wp-block-latest-posts__post-excerpt\">Curr Opin Immunol. 2026 Apr 8;100:102776. doi: 10.1016\/j.coi.2026.102776. Online ahead of print. ABSTRACT Artificial intelligence (AI) and machine learning are widely promoted as transformative tools for medical practice, yet their impact in daily rheumatology remains limited. This review examines the gap between expectations and reality using historical parallels, conceptual considerations, and recent methodological evidence. Experiences &#8230; <a title=\"Why we need to maintain a critical view on big data and artificial intelligence predictions\" class=\"read-more\" href=\"https:\/\/inmuno.es\/index.php\/2026\/04\/10\/why-we-need-to-maintain-a-critical-view-on-big-data-and-artificial-intelligence-predictions\/\" aria-label=\"Read more about Why we need to maintain a critical view on big data and artificial intelligence predictions\">Read more<\/a><\/div><\/li>\n<li><a class=\"wp-block-latest-posts__post-title\" href=\"https:\/\/inmuno.es\/index.php\/2026\/04\/10\/why-sjogrens-disease\/\">Why Sj\u00f6gren&#8217;s disease?<\/a><div class=\"wp-block-latest-posts__post-author\">by inmunoadmin<\/div><time datetime=\"2026-04-10T06:53:00+02:00\" class=\"wp-block-latest-posts__post-date\">10 de April de 2026<\/time><div class=\"wp-block-latest-posts__post-excerpt\">Curr Opin Immunol. 2026 Apr 8;100:102772. doi: 10.1016\/j.coi.2026.102772. Online ahead of print. ABSTRACT This paper reviews the historical development, pathogenesis, and nomenclature of Sj\u00f6gren&#8217;s syndrome and critiques the recently proposed term &#8216;Sj\u00f6gren&#8217;s disease&#8217;. Early clinical observations gradually defined the disorder as a systemic condition characterized by sicca symptoms and frequent extraglandular involvement. Advances in immunology &#8230; <a title=\"Why Sj\u00f6gren&#8217;s disease?\" class=\"read-more\" href=\"https:\/\/inmuno.es\/index.php\/2026\/04\/10\/why-sjogrens-disease\/\" aria-label=\"Read more about Why Sj\u00f6gren&#8217;s disease?\">Read more<\/a><\/div><\/li>\n<li><a class=\"wp-block-latest-posts__post-title\" href=\"https:\/\/inmuno.es\/index.php\/2026\/04\/09\/%ce%b22-glycoprotein-i-structure-mechanisms-of-autoantibody-recognition-and-polymorphisms\/\">\u03b22-Glycoprotein I: structure, mechanisms of autoantibody recognition, and polymorphisms<\/a><div class=\"wp-block-latest-posts__post-author\">by inmunoadmin<\/div><time datetime=\"2026-04-09T07:26:38+02:00\" class=\"wp-block-latest-posts__post-date\">9 de April de 2026<\/time><div class=\"wp-block-latest-posts__post-excerpt\">Curr Opin Immunol. 2026 Apr 7;100:102771. doi: 10.1016\/j.coi.2026.102771. Online ahead of print. ABSTRACT Identified in the 1990s as the primary target of antiphospholipid antibodies (aPL) in antiphospholipid syndrome (APS), \u03b22-glycoprotein I (\u03b22GPI) remains a central focus in hematology and immunology. Anti-\u03b22GPI antibodies are important not only for diagnosing APS but also play a key role &#8230; <a title=\"\u03b22-Glycoprotein I: structure, mechanisms of autoantibody recognition, and polymorphisms\" class=\"read-more\" href=\"https:\/\/inmuno.es\/index.php\/2026\/04\/09\/%ce%b22-glycoprotein-i-structure-mechanisms-of-autoantibody-recognition-and-polymorphisms\/\" aria-label=\"Read more about \u03b22-Glycoprotein I: structure, mechanisms of autoantibody recognition, and polymorphisms\">Read more<\/a><\/div><\/li>\n<li><a class=\"wp-block-latest-posts__post-title\" href=\"https:\/\/inmuno.es\/index.php\/2026\/04\/04\/the-mitochondrial-metabolic-shift-in-inflammatory-monocytes-during-plasmodium-vivax-malaria\/\">The mitochondrial metabolic shift in inflammatory monocytes during Plasmodium vivax malaria<\/a><div class=\"wp-block-latest-posts__post-author\">by inmunoadmin<\/div><time datetime=\"2026-04-04T06:34:17+02:00\" class=\"wp-block-latest-posts__post-date\">4 de April de 2026<\/time><div class=\"wp-block-latest-posts__post-excerpt\">Curr Opin Immunol. 2026 Apr 2;100:102769. doi: 10.1016\/j.coi.2026.102769. Online ahead of print. ABSTRACT Although immunometabolism has emerged as a central area of research in infectious diseases, only a few studies have focused on Plasmodium vivax infection. Here, we discuss the results obtained in our laboratory and elsewhere that show a metabolic-mitochondria shift in highly activated &#8230; <a title=\"The mitochondrial metabolic shift in inflammatory monocytes during Plasmodium vivax malaria\" class=\"read-more\" href=\"https:\/\/inmuno.es\/index.php\/2026\/04\/04\/the-mitochondrial-metabolic-shift-in-inflammatory-monocytes-during-plasmodium-vivax-malaria\/\" aria-label=\"Read more about The mitochondrial metabolic shift in inflammatory monocytes during Plasmodium vivax malaria\">Read more<\/a><\/div><\/li>\n<li><a class=\"wp-block-latest-posts__post-title\" href=\"https:\/\/inmuno.es\/index.php\/2026\/04\/01\/from-disease-to-syndrome-the-evolution-of-parkinsons-as-a-heterogeneous-entity\/\">From disease to syndrome: the evolution of Parkinson&#8217;s as a heterogeneous entity<\/a><div class=\"wp-block-latest-posts__post-author\">by inmunoadmin<\/div><time datetime=\"2026-04-01T06:54:49+02:00\" class=\"wp-block-latest-posts__post-date\">1 de April de 2026<\/time><div class=\"wp-block-latest-posts__post-excerpt\">Curr Opin Immunol. 2026 Mar 30;100:102759. doi: 10.1016\/j.coi.2026.102759. Online ahead of print. ABSTRACT Parkinson&#8217;s disease (PD) is increasingly recognised as a multifactorial and heterogeneous condition rather than a single uniform disorder, supported by advances in molecular biology, genetics and pathology. This review provides a perspective on the shifting concept of PD from an idiopathic, strictly &#8230; <a title=\"From disease to syndrome: the evolution of Parkinson&#8217;s as a heterogeneous entity\" class=\"read-more\" href=\"https:\/\/inmuno.es\/index.php\/2026\/04\/01\/from-disease-to-syndrome-the-evolution-of-parkinsons-as-a-heterogeneous-entity\/\" aria-label=\"Read more about From disease to syndrome: the evolution of Parkinson&#8217;s as a heterogeneous entity\">Read more<\/a><\/div><\/li>\n<li><a class=\"wp-block-latest-posts__post-title\" href=\"https:\/\/inmuno.es\/index.php\/2026\/03\/30\/a-liver-mitochondria-immune-axis-in-parkinsons-disease-emerging-perspectives-on-a-hepatic-origin-for-mitochondrial-autoimmunity-as-a-driver-of-parkinsons-disease\/\">A liver-mitochondria-immune axis in Parkinson&#8217;s disease: emerging perspectives on a hepatic origin for mitochondrial autoimmunity as a driver of Parkinson&#8217;s disease<\/a><div class=\"wp-block-latest-posts__post-author\">by inmunoadmin<\/div><time datetime=\"2026-03-30T07:09:44+02:00\" class=\"wp-block-latest-posts__post-date\">30 de March de 2026<\/time><div class=\"wp-block-latest-posts__post-excerpt\">Curr Opin Immunol. 2026 Mar 28;100:102761. doi: 10.1016\/j.coi.2026.102761. Online ahead of print. ABSTRACT Parkinson&#8217;s disease (PD) is increasingly understood as a systemic disorder with early manifestations outside the central nervous system. Converging clinical, metabolic, and immunological observations highlight overlaps between PD and primary biliary cholangitis (PBC), a prototypic autoimmune cholestatic liver disease. A shared hallmark &#8230; <a title=\"A liver-mitochondria-immune axis in Parkinson&#8217;s disease: emerging perspectives on a hepatic origin for mitochondrial autoimmunity as a driver of Parkinson&#8217;s disease\" class=\"read-more\" href=\"https:\/\/inmuno.es\/index.php\/2026\/03\/30\/a-liver-mitochondria-immune-axis-in-parkinsons-disease-emerging-perspectives-on-a-hepatic-origin-for-mitochondrial-autoimmunity-as-a-driver-of-parkinsons-disease\/\" aria-label=\"Read more about A liver-mitochondria-immune axis in Parkinson&#8217;s disease: emerging perspectives on a hepatic origin for mitochondrial autoimmunity as a driver of Parkinson&#8217;s disease\">Read more<\/a><\/div><\/li>\n<li><a class=\"wp-block-latest-posts__post-title\" href=\"https:\/\/inmuno.es\/index.php\/2026\/03\/28\/neutrophils-and-monocytes-in-the-pathogenesis-of-antiphospholipid-syndrome\/\">Neutrophils and monocytes in the pathogenesis of antiphospholipid syndrome<\/a><div class=\"wp-block-latest-posts__post-author\">by inmunoadmin<\/div><time datetime=\"2026-03-28T05:57:14+01:00\" class=\"wp-block-latest-posts__post-date\">28 de March de 2026<\/time><div class=\"wp-block-latest-posts__post-excerpt\">Curr Opin Immunol. 2026 Mar 26;100:102768. doi: 10.1016\/j.coi.2026.102768. Online ahead of print. ABSTRACT Antiphospholipid syndrome (APS) is an autoimmune thromboinflammatory disorder in which antiphospholipid antibodies cause vascular thrombosis and obstetric morbidity. Growing evidence indicates that neutrophils and monocytes are key effector cells bridging inflammation and coagulation in APS. Neutrophils display heightened activation, enhanced glycolysis, and &#8230; <a title=\"Neutrophils and monocytes in the pathogenesis of antiphospholipid syndrome\" class=\"read-more\" href=\"https:\/\/inmuno.es\/index.php\/2026\/03\/28\/neutrophils-and-monocytes-in-the-pathogenesis-of-antiphospholipid-syndrome\/\" aria-label=\"Read more about Neutrophils and monocytes in the pathogenesis of antiphospholipid syndrome\">Read more<\/a><\/div><\/li>\n<li><a class=\"wp-block-latest-posts__post-title\" href=\"https:\/\/inmuno.es\/index.php\/2026\/03\/25\/gut-microbiota-in-pathogenesis-and-therapeutic-potentials-in-rheumatoid-arthritis\/\">Gut microbiota in pathogenesis and therapeutic potentials in rheumatoid arthritis<\/a><div class=\"wp-block-latest-posts__post-author\">by inmunoadmin<\/div><time datetime=\"2026-03-25T06:31:56+01:00\" class=\"wp-block-latest-posts__post-date\">25 de March de 2026<\/time><div class=\"wp-block-latest-posts__post-excerpt\">Curr Opin Immunol. 2026 Mar 23;100:102760. doi: 10.1016\/j.coi.2026.102760. Online ahead of print. ABSTRACT This review comprehensively explores the emerging roles of gut microbiota in the pathogenesis and therapeutic implications of rheumatoid arthritis (RA). Clinically, RA is a challenging autoimmune disease due to unclear pathology and limitations of conventional therapies. Recent studies highlight that gut dysbiosis &#8230; <a title=\"Gut microbiota in pathogenesis and therapeutic potentials in rheumatoid arthritis\" class=\"read-more\" href=\"https:\/\/inmuno.es\/index.php\/2026\/03\/25\/gut-microbiota-in-pathogenesis-and-therapeutic-potentials-in-rheumatoid-arthritis\/\" aria-label=\"Read more about Gut microbiota in pathogenesis and therapeutic potentials in rheumatoid arthritis\">Read more<\/a><\/div><\/li>\n<li><a class=\"wp-block-latest-posts__post-title\" href=\"https:\/\/inmuno.es\/index.php\/2026\/03\/18\/mpox-emergence-and-new-vaccines-a-story-of-susceptibility\/\">Mpox emergence and new vaccines: a story of susceptibility<\/a><div class=\"wp-block-latest-posts__post-author\">by inmunoadmin<\/div><time datetime=\"2026-03-18T06:50:12+01:00\" class=\"wp-block-latest-posts__post-date\">18 de March de 2026<\/time><div class=\"wp-block-latest-posts__post-excerpt\">Curr Opin Immunol. 2026 Mar 16;100:102755. doi: 10.1016\/j.coi.2026.102755. Online ahead of print. ABSTRACT Mpox is a smallpox-like disease caused by the monkeypox virus. In 2022, a global outbreak of mpox resulted in more than 113 000 cases. Just a year later, a different strain of mpox caused the largest ever outbreak in Africa, with over &#8230; <a title=\"Mpox emergence and new vaccines: a story of susceptibility\" class=\"read-more\" href=\"https:\/\/inmuno.es\/index.php\/2026\/03\/18\/mpox-emergence-and-new-vaccines-a-story-of-susceptibility\/\" aria-label=\"Read more about Mpox emergence and new vaccines: a story of susceptibility\">Read more<\/a><\/div><\/li>\n<li><a class=\"wp-block-latest-posts__post-title\" href=\"https:\/\/inmuno.es\/index.php\/2026\/03\/18\/a-critical-look-at-the-evolution-of-randomized-controlled-trials-new-and-old-ethical-issues\/\">A critical look at the evolution of randomized controlled trials: new and old ethical issues<\/a><div class=\"wp-block-latest-posts__post-author\">by inmunoadmin<\/div><time datetime=\"2026-03-18T06:50:12+01:00\" class=\"wp-block-latest-posts__post-date\">18 de March de 2026<\/time><div class=\"wp-block-latest-posts__post-excerpt\">Curr Opin Immunol. 2026 Mar 16;100:102758. doi: 10.1016\/j.coi.2026.102758. Online ahead of print. ABSTRACT The traditional randomized controlled trial (RCT), a most valuable tool of evidence-based medicine, is rapidly evolving into new forms. The main reason behind this evolution is the basic explanatory nature of RCT and the related need for real-world data to help with &#8230; <a title=\"A critical look at the evolution of randomized controlled trials: new and old ethical issues\" class=\"read-more\" href=\"https:\/\/inmuno.es\/index.php\/2026\/03\/18\/a-critical-look-at-the-evolution-of-randomized-controlled-trials-new-and-old-ethical-issues\/\" aria-label=\"Read more about A critical look at the evolution of randomized controlled trials: new and old ethical issues\">Read more<\/a><\/div><\/li>\n<li><a class=\"wp-block-latest-posts__post-title\" href=\"https:\/\/inmuno.es\/index.php\/2026\/03\/18\/immune-dyshomeostasis-in-lifestyle-associated-diseases-a-new-paradigm-for-personalized-medicine-and-prevention\/\">Immune dyshomeostasis in lifestyle-associated diseases: a new paradigm for personalized medicine and prevention<\/a><div class=\"wp-block-latest-posts__post-author\">by inmunoadmin<\/div><time datetime=\"2026-03-18T06:50:11+01:00\" class=\"wp-block-latest-posts__post-date\">18 de March de 2026<\/time><div class=\"wp-block-latest-posts__post-excerpt\">Curr Opin Immunol. 2026 Mar 16;100:102754. doi: 10.1016\/j.coi.2026.102754. Online ahead of print. ABSTRACT Non-communicable diseases, including metabolic, inflammatory, and malignant disorders, now dominate global morbidity and mortality. These chronic, lifestyle-associated diseases expose the limits of strategies focused on suppressing late-stage inflammation. We argue that immune dyshomeostasis &#8211; rather than overt inflammation &#8211; represents the more &#8230; <a title=\"Immune dyshomeostasis in lifestyle-associated diseases: a new paradigm for personalized medicine and prevention\" class=\"read-more\" href=\"https:\/\/inmuno.es\/index.php\/2026\/03\/18\/immune-dyshomeostasis-in-lifestyle-associated-diseases-a-new-paradigm-for-personalized-medicine-and-prevention\/\" aria-label=\"Read more about Immune dyshomeostasis in lifestyle-associated diseases: a new paradigm for personalized medicine and prevention\">Read more<\/a><\/div><\/li>\n<li><a class=\"wp-block-latest-posts__post-title\" href=\"https:\/\/inmuno.es\/index.php\/2026\/03\/16\/functional-interactions-of-kv1-3-channels-in-microglia-and-t-cells-and-their-implications-in-neurodegeneration\/\">Functional interactions of Kv1.3 channels in microglia and T cells and their implications in neurodegeneration<\/a><div class=\"wp-block-latest-posts__post-author\">by inmunoadmin<\/div><time datetime=\"2026-03-16T05:51:22+01:00\" class=\"wp-block-latest-posts__post-date\">16 de March de 2026<\/time><div class=\"wp-block-latest-posts__post-excerpt\">Curr Opin Immunol. 2026 Mar 14;100:102757. doi: 10.1016\/j.coi.2026.102757. Online ahead of print. ABSTRACT Kv1.3 is a voltage-gated potassium channel expressed on immune cells. It functions in coordination with calcium channels to maintain cellular homeostasis. Several studies support important roles for Kv1.3 in microglia-driven neuroinflammation and T cell-mediated autoimmunity. Based on recent evidence, Kv1.3 may regulate &#8230; <a title=\"Functional interactions of Kv1.3 channels in microglia and T cells and their implications in neurodegeneration\" class=\"read-more\" href=\"https:\/\/inmuno.es\/index.php\/2026\/03\/16\/functional-interactions-of-kv1-3-channels-in-microglia-and-t-cells-and-their-implications-in-neurodegeneration\/\" aria-label=\"Read more about Functional interactions of Kv1.3 channels in microglia and T cells and their implications in neurodegeneration\">Read more<\/a><\/div><\/li>\n<li><a class=\"wp-block-latest-posts__post-title\" href=\"https:\/\/inmuno.es\/index.php\/2026\/03\/15\/malaria-immunity-in-the-infant-progress-and-pitfalls\/\">Malaria immunity in the infant: progress and pitfalls<\/a><div class=\"wp-block-latest-posts__post-author\">by inmunoadmin<\/div><time datetime=\"2026-03-15T11:28:20+01:00\" class=\"wp-block-latest-posts__post-date\">15 de March de 2026<\/time><div class=\"wp-block-latest-posts__post-excerpt\">Curr Opin Immunol. 2026 Mar 13;100:102756. doi: 10.1016\/j.coi.2026.102756. Online ahead of print. ABSTRACT We are at the dawn of a new era in the biomedical prevention of childhood malaria. The successful development and ongoing rollout of the first malaria vaccines, RTS,S\/AS01E and R21\/Matrix-M, have injected much-needed optimism into the malaria prevention field. Additional new vaccines &#8230; <a title=\"Malaria immunity in the infant: progress and pitfalls\" class=\"read-more\" href=\"https:\/\/inmuno.es\/index.php\/2026\/03\/15\/malaria-immunity-in-the-infant-progress-and-pitfalls\/\" aria-label=\"Read more about Malaria immunity in the infant: progress and pitfalls\">Read more<\/a><\/div><\/li>\n<li><a class=\"wp-block-latest-posts__post-title\" href=\"https:\/\/inmuno.es\/index.php\/2026\/03\/14\/p2-purinergic-receptors-in-systemic-lupus-erythematosus-from-experimental-findings-to-therapeutic-perspectives\/\">P2 purinergic receptors in systemic lupus erythematosus: from experimental findings to therapeutic perspectives<\/a><div class=\"wp-block-latest-posts__post-author\">by inmunoadmin<\/div><time datetime=\"2026-03-14T05:47:56+01:00\" class=\"wp-block-latest-posts__post-date\">14 de March de 2026<\/time><div class=\"wp-block-latest-posts__post-excerpt\">Curr Opin Immunol. 2026 Mar 12;100:102752. doi: 10.1016\/j.coi.2026.102752. Online ahead of print. ABSTRACT P2 purinergic receptors are activated by extracellular adenosine triphosphate and other nucleotides released during inflammatory processes, cellular stress responses, and amplification by NETosis, thereby serving as pivotal mediators of both innate and adaptive immunity. In patients with active systemic lupus erythematosus (SLE), &#8230; <a title=\"P2 purinergic receptors in systemic lupus erythematosus: from experimental findings to therapeutic perspectives\" class=\"read-more\" href=\"https:\/\/inmuno.es\/index.php\/2026\/03\/14\/p2-purinergic-receptors-in-systemic-lupus-erythematosus-from-experimental-findings-to-therapeutic-perspectives\/\" aria-label=\"Read more about P2 purinergic receptors in systemic lupus erythematosus: from experimental findings to therapeutic perspectives\">Read more<\/a><\/div><\/li>\n<li><a class=\"wp-block-latest-posts__post-title\" href=\"https:\/\/inmuno.es\/index.php\/2026\/03\/12\/current-role-of-atg-in-gvhd-prevention-optimizing-post-transplantation-outcomes-through-combination-with-ptcy\/\">Current role of ATG in GVHD prevention: optimizing post-transplantation outcomes through combination with PTCY<\/a><div class=\"wp-block-latest-posts__post-author\">by inmunoadmin<\/div><time datetime=\"2026-03-12T06:59:59+01:00\" class=\"wp-block-latest-posts__post-date\">12 de March de 2026<\/time><div class=\"wp-block-latest-posts__post-excerpt\">Curr Opin Immunol. 2026 Mar 10;100:102749. doi: 10.1016\/j.coi.2026.102749. Online ahead of print. ABSTRACT Graft versus host disease (GVHD) is one of the major complications of allogeneic hematopoietic cell transplantation (allo-HCT), contributing significantly to post-transplant morbidity and mortality. Anti-thymocyte globulin (ATG) is a widely used GVHD prophylaxis in combination with a calcineurin inhibitor and an antimetabolite. &#8230; <a title=\"Current role of ATG in GVHD prevention: optimizing post-transplantation outcomes through combination with PTCY\" class=\"read-more\" href=\"https:\/\/inmuno.es\/index.php\/2026\/03\/12\/current-role-of-atg-in-gvhd-prevention-optimizing-post-transplantation-outcomes-through-combination-with-ptcy\/\" aria-label=\"Read more about Current role of ATG in GVHD prevention: optimizing post-transplantation outcomes through combination with PTCY\">Read more<\/a><\/div><\/li>\n<li><a class=\"wp-block-latest-posts__post-title\" href=\"https:\/\/inmuno.es\/index.php\/2026\/03\/12\/use-of-synthetic-data-a-novel-paradigm-for-immunopathology\/\">Use of synthetic data, a novel paradigm for immunopathology<\/a><div class=\"wp-block-latest-posts__post-author\">by inmunoadmin<\/div><time datetime=\"2026-03-12T06:59:59+01:00\" class=\"wp-block-latest-posts__post-date\">12 de March de 2026<\/time><div class=\"wp-block-latest-posts__post-excerpt\">Curr Opin Immunol. 2026 Mar 10;100:102753. doi: 10.1016\/j.coi.2026.102753. Online ahead of print. ABSTRACT The complexity and heterogeneity of autoimmune diseases are only partially captured by current analytic tools, even when deep learning techniques are employed to intercept patterns beyond existing dogma. Synthetic data offer a newer paradigm through machine-generated reconstructions of real-world data that faithfully &#8230; <a title=\"Use of synthetic data, a novel paradigm for immunopathology\" class=\"read-more\" href=\"https:\/\/inmuno.es\/index.php\/2026\/03\/12\/use-of-synthetic-data-a-novel-paradigm-for-immunopathology\/\" aria-label=\"Read more about Use of synthetic data, a novel paradigm for immunopathology\">Read more<\/a><\/div><\/li>\n<li><a class=\"wp-block-latest-posts__post-title\" href=\"https:\/\/inmuno.es\/index.php\/2026\/03\/12\/autoimmunity-beyond-antibodies-alternative-roles-of-beta-2-glycoprotein-i-in-and-out-of-antiphospholipid-syndrome\/\">Autoimmunity beyond antibodies: alternative roles of beta-2-glycoprotein I in and out of antiphospholipid syndrome?<\/a><div class=\"wp-block-latest-posts__post-author\">by inmunoadmin<\/div><time datetime=\"2026-03-12T06:59:59+01:00\" class=\"wp-block-latest-posts__post-date\">12 de March de 2026<\/time><div class=\"wp-block-latest-posts__post-excerpt\">Curr Opin Immunol. 2026 Mar 10;100:102748. doi: 10.1016\/j.coi.2026.102748. Online ahead of print. ABSTRACT The term autoimmune disease refers to autoantibody-dependent pathophysiological conditions, in which characterising the autoantibodies is essential, as is studying their target(s), the (auto)antigen(s), which represent the other side of the coin. In this review, we aimed to go further inside the ultimate &#8230; <a title=\"Autoimmunity beyond antibodies: alternative roles of beta-2-glycoprotein I in and out of antiphospholipid syndrome?\" class=\"read-more\" href=\"https:\/\/inmuno.es\/index.php\/2026\/03\/12\/autoimmunity-beyond-antibodies-alternative-roles-of-beta-2-glycoprotein-i-in-and-out-of-antiphospholipid-syndrome\/\" aria-label=\"Read more about Autoimmunity beyond antibodies: alternative roles of beta-2-glycoprotein I in and out of antiphospholipid syndrome?\">Read more<\/a><\/div><\/li>\n<li><a class=\"wp-block-latest-posts__post-title\" href=\"https:\/\/inmuno.es\/index.php\/2026\/03\/05\/beyond-ion-flux-the-potassium-channel-kv1-3-and-its-regulatory-function-in-neutrophils\/\">Beyond ion flux: the potassium channel KV1.3 and its regulatory function in neutrophils<\/a><div class=\"wp-block-latest-posts__post-author\">by inmunoadmin<\/div><time datetime=\"2026-03-05T01:20:04+01:00\" class=\"wp-block-latest-posts__post-date\">5 de March de 2026<\/time><div class=\"wp-block-latest-posts__post-excerpt\">Curr Opin Immunol. 2026 Mar 3;100:102750. doi: 10.1016\/j.coi.2026.102750. Online ahead of print. ABSTRACT The voltage-gated potassium channel KV1.3 (KCNA3) is a critical ion channel regulating membrane potential in immune cells, facilitating sustained calcium influx and activating downstream signaling events. Besides its canonical role as an ion channel, KV1.3 has been postulated to exert additional functions &#8230; <a title=\"Beyond ion flux: the potassium channel KV1.3 and its regulatory function in neutrophils\" class=\"read-more\" href=\"https:\/\/inmuno.es\/index.php\/2026\/03\/05\/beyond-ion-flux-the-potassium-channel-kv1-3-and-its-regulatory-function-in-neutrophils\/\" aria-label=\"Read more about Beyond ion flux: the potassium channel KV1.3 and its regulatory function in neutrophils\">Read more<\/a><\/div><\/li>\n<li><a class=\"wp-block-latest-posts__post-title\" href=\"https:\/\/inmuno.es\/index.php\/2026\/03\/05\/amyloid-precursor-protein-is-a-subunit-of-microglial-hv1-channels\/\">Amyloid precursor protein is a subunit of microglial Hv1 channels<\/a><div class=\"wp-block-latest-posts__post-author\">by inmunoadmin<\/div><time datetime=\"2026-03-05T01:20:04+01:00\" class=\"wp-block-latest-posts__post-date\">5 de March de 2026<\/time><div class=\"wp-block-latest-posts__post-excerpt\">Curr Opin Immunol. 2026 Mar 3;100:102751. doi: 10.1016\/j.coi.2026.102751. Online ahead of print. ABSTRACT Voltage-gated proton channels (Hv1) are key regulators of microglial activation, coupling proton extrusion to reactive oxygen species production, cellular pH homeostasis, and pro-inflammatory signaling. Dysregulated Hv1 activity exacerbates neuroinflammation and contributes to a range of central nervous system pathologies. Our recent work &#8230; <a title=\"Amyloid precursor protein is a subunit of microglial Hv1 channels\" class=\"read-more\" href=\"https:\/\/inmuno.es\/index.php\/2026\/03\/05\/amyloid-precursor-protein-is-a-subunit-of-microglial-hv1-channels\/\" aria-label=\"Read more about Amyloid precursor protein is a subunit of microglial Hv1 channels\">Read more<\/a><\/div><\/li>\n<li><a class=\"wp-block-latest-posts__post-title\" href=\"https:\/\/inmuno.es\/index.php\/2026\/03\/05\/clinical-trials-and-new-therapies-in-sjogrens-disease\/\">Clinical trials and new therapies in Sj\u00f6gren&#8217;s disease<\/a><div class=\"wp-block-latest-posts__post-author\">by inmunoadmin<\/div><time datetime=\"2026-03-05T01:20:04+01:00\" class=\"wp-block-latest-posts__post-date\">5 de March de 2026<\/time><div class=\"wp-block-latest-posts__post-excerpt\">Curr Opin Immunol. 2026 Mar 3;100:102743. doi: 10.1016\/j.coi.2026.102743. Online ahead of print. ABSTRACT Despite major advances in understanding Sj\u00f6gren&#8217;s disease (SjD), no approved disease-modifying therapies have been approved. Management remains largely symptomatic with the use of off-label immunomodulators for systemic features. This gap highlights the substantial unmet need for targeted treatment. Encouragingly, the therapeutic landscape &#8230; <a title=\"Clinical trials and new therapies in Sj\u00f6gren&#8217;s disease\" class=\"read-more\" href=\"https:\/\/inmuno.es\/index.php\/2026\/03\/05\/clinical-trials-and-new-therapies-in-sjogrens-disease\/\" aria-label=\"Read more about Clinical trials and new therapies in Sj\u00f6gren&#8217;s disease\">Read more<\/a><\/div><\/li>\n<li><a class=\"wp-block-latest-posts__post-title\" href=\"https:\/\/inmuno.es\/index.php\/2026\/03\/05\/targeting-synovial-fibroblast-kca1-1-channels-in-rheumatoid-arthritis\/\">Targeting synovial fibroblast KCa1.1 channels in rheumatoid arthritis<\/a><div class=\"wp-block-latest-posts__post-author\">by inmunoadmin<\/div><time datetime=\"2026-03-05T01:20:04+01:00\" class=\"wp-block-latest-posts__post-date\">5 de March de 2026<\/time><div class=\"wp-block-latest-posts__post-excerpt\">Curr Opin Immunol. 2026 Mar 3;100:102747. doi: 10.1016\/j.coi.2026.102747. Online ahead of print. ABSTRACT Fibroblast-like synoviocytes (FLS) play major roles in the pathogenesis of rheumatoid arthritis (RA). Human and rat FLS express the KCa1.1 channel (BK, Maxi-K, Slo1, and KCNMA1) as their major potassium channel at the plasma membrane. Reducing the expression or function of this &#8230; <a title=\"Targeting synovial fibroblast KCa1.1 channels in rheumatoid arthritis\" class=\"read-more\" href=\"https:\/\/inmuno.es\/index.php\/2026\/03\/05\/targeting-synovial-fibroblast-kca1-1-channels-in-rheumatoid-arthritis\/\" aria-label=\"Read more about Targeting synovial fibroblast KCa1.1 channels in rheumatoid arthritis\">Read more<\/a><\/div><\/li>\n<li><a class=\"wp-block-latest-posts__post-title\" href=\"https:\/\/inmuno.es\/index.php\/2026\/03\/04\/endothelial-dysfunction-in-aps-advancing-pathophysiological-understanding-to-improve-management\/\">Endothelial dysfunction in APS: advancing pathophysiological understanding to improve management<\/a><div class=\"wp-block-latest-posts__post-author\">by inmunoadmin<\/div><time datetime=\"2026-03-04T07:59:53+01:00\" class=\"wp-block-latest-posts__post-date\">4 de March de 2026<\/time><div class=\"wp-block-latest-posts__post-excerpt\">Curr Opin Immunol. 2026 Mar 2;100:102745. doi: 10.1016\/j.coi.2026.102745. Online ahead of print. ABSTRACT Endothelial dysfunction (ED) is a hallmark of antiphospholipid syndrome (APS) driven by chronic antiphospholipid antibody (aPL) exposure. Beyond acute thrombotic events, ED contributes to atherosclerosis, vascular remodelling, stenosis and multi-organ manifestations, positioning the endothelium as a putative target for disease monitoring and &#8230; <a title=\"Endothelial dysfunction in APS: advancing pathophysiological understanding to improve management\" class=\"read-more\" href=\"https:\/\/inmuno.es\/index.php\/2026\/03\/04\/endothelial-dysfunction-in-aps-advancing-pathophysiological-understanding-to-improve-management\/\" aria-label=\"Read more about Endothelial dysfunction in APS: advancing pathophysiological understanding to improve management\">Read more<\/a><\/div><\/li>\n<li><a class=\"wp-block-latest-posts__post-title\" href=\"https:\/\/inmuno.es\/index.php\/2026\/03\/01\/mpox-virus-immunology-exploring-links-to-autoimmune-diseases\/\">Mpox virus immunology: exploring links to autoimmune diseases<\/a><div class=\"wp-block-latest-posts__post-author\">by inmunoadmin<\/div><time datetime=\"2026-03-01T07:04:58+01:00\" class=\"wp-block-latest-posts__post-date\">1 de March de 2026<\/time><div class=\"wp-block-latest-posts__post-excerpt\">Curr Opin Immunol. 2026 Feb 27;99:102744. doi: 10.1016\/j.coi.2026.102744. Online ahead of print. ABSTRACT The reemergence of the mpox virus (MPXV) as a global health threat, with &gt;100 000 cases reported across 115 countries since the WHO&#8217;s 2022 alert, has intensified research into its pathophysiology. MPXV exists in two main clades with distinct geographic and clinical &#8230; <a title=\"Mpox virus immunology: exploring links to autoimmune diseases\" class=\"read-more\" href=\"https:\/\/inmuno.es\/index.php\/2026\/03\/01\/mpox-virus-immunology-exploring-links-to-autoimmune-diseases\/\" aria-label=\"Read more about Mpox virus immunology: exploring links to autoimmune diseases\">Read more<\/a><\/div><\/li>\n<li><a class=\"wp-block-latest-posts__post-title\" href=\"https:\/\/inmuno.es\/index.php\/2026\/03\/01\/addressing-unmet-needs-in-rheumatoid-arthritis-the-challenge-of-translating-multi-omics-into-precision-therapies\/\">Addressing unmet needs in rheumatoid arthritis: the challenge of translating multi-omics into precision therapies<\/a><div class=\"wp-block-latest-posts__post-author\">by inmunoadmin<\/div><time datetime=\"2026-03-01T07:04:58+01:00\" class=\"wp-block-latest-posts__post-date\">1 de March de 2026<\/time><div class=\"wp-block-latest-posts__post-excerpt\">Curr Opin Immunol. 2026 Feb 27;99:102742. doi: 10.1016\/j.coi.2026.102742. Online ahead of print. ABSTRACT Rheumatoid arthritis (RA) is a highly heterogeneous chronic systemic inflammatory disease. Approximately 30-40% of patients exhibit an inadequate response to currently available biologic agents and Janus kinase inhibitors. In recent years, rapid advances in multi-omics technologies, including genomics, temporal transcriptomics, proteomics, metabolomics, &#8230; <a title=\"Addressing unmet needs in rheumatoid arthritis: the challenge of translating multi-omics into precision therapies\" class=\"read-more\" href=\"https:\/\/inmuno.es\/index.php\/2026\/03\/01\/addressing-unmet-needs-in-rheumatoid-arthritis-the-challenge-of-translating-multi-omics-into-precision-therapies\/\" aria-label=\"Read more about Addressing unmet needs in rheumatoid arthritis: the challenge of translating multi-omics into precision therapies\">Read more<\/a><\/div><\/li>\n<li><a class=\"wp-block-latest-posts__post-title\" href=\"https:\/\/inmuno.es\/index.php\/2026\/03\/01\/composite-and-pragmatic-measures-in-psoriatic-arthritis-bridging-trials-and-clinical-feasibility\/\">Composite and pragmatic measures in psoriatic arthritis: bridging trials and clinical feasibility<\/a><div class=\"wp-block-latest-posts__post-author\">by inmunoadmin<\/div><time datetime=\"2026-03-01T07:04:58+01:00\" class=\"wp-block-latest-posts__post-date\">1 de March de 2026<\/time><div class=\"wp-block-latest-posts__post-excerpt\">Curr Opin Immunol. 2026 Feb 27;99:102746. doi: 10.1016\/j.coi.2026.102746. Online ahead of print. ABSTRACT PURPOSE OF REVIEW: Psoriatic arthritis (PsA) is a multidomain inflammatory disease where no instrument captures the full spectrum of activity or its impact on patients&#8217; lives. Accurate outcome measurement is essential for research and personalized care. This review summarizes advances in PsA &#8230; <a title=\"Composite and pragmatic measures in psoriatic arthritis: bridging trials and clinical feasibility\" class=\"read-more\" href=\"https:\/\/inmuno.es\/index.php\/2026\/03\/01\/composite-and-pragmatic-measures-in-psoriatic-arthritis-bridging-trials-and-clinical-feasibility\/\" aria-label=\"Read more about Composite and pragmatic measures in psoriatic arthritis: bridging trials and clinical feasibility\">Read more<\/a><\/div><\/li>\n<li><a class=\"wp-block-latest-posts__post-title\" href=\"https:\/\/inmuno.es\/index.php\/2026\/02\/20\/evolution-and-prospects-for-the-definition-of-clinically-useful-endpoints-in-sjogren-disease\/\">Evolution and prospects for the definition of clinically useful endpoints in Sj\u00f6gren disease<\/a><div class=\"wp-block-latest-posts__post-author\">by inmunoadmin<\/div><time datetime=\"2026-02-20T06:49:15+01:00\" class=\"wp-block-latest-posts__post-date\">20 de February de 2026<\/time><div class=\"wp-block-latest-posts__post-excerpt\">Curr Opin Immunol. 2026 Feb 18;99:102741. doi: 10.1016\/j.coi.2026.102741. Online ahead of print. ABSTRACT Outcomes in Sj\u00f6gren disease (SjD) have ranged from diverse symptom scales to the validated EULAR Sj\u00f6gren&#8217;s Syndrome Patient Reported Index (ESSPRI) and EULAR Sj\u00f6gren&#8217;s Syndrome Disease Activity Index (ESSDAI), which now provide a common framework for evaluating symptoms and systemic activity. In &#8230; <a title=\"Evolution and prospects for the definition of clinically useful endpoints in Sj\u00f6gren disease\" class=\"read-more\" href=\"https:\/\/inmuno.es\/index.php\/2026\/02\/20\/evolution-and-prospects-for-the-definition-of-clinically-useful-endpoints-in-sjogren-disease\/\" aria-label=\"Read more about Evolution and prospects for the definition of clinically useful endpoints in Sj\u00f6gren disease\">Read more<\/a><\/div><\/li>\n<li><a class=\"wp-block-latest-posts__post-title\" href=\"https:\/\/inmuno.es\/index.php\/2026\/02\/19\/antimicrobial-peptides-and-proteins-as-rheostats-of-intestinal-homeostasis-and-immunity\/\">Antimicrobial peptides and proteins as rheostats of intestinal homeostasis and immunity<\/a><div class=\"wp-block-latest-posts__post-author\">by inmunoadmin<\/div><time datetime=\"2026-02-19T08:21:40+01:00\" class=\"wp-block-latest-posts__post-date\">19 de February de 2026<\/time><div class=\"wp-block-latest-posts__post-excerpt\">Curr Opin Immunol. 2026 Feb 17;99:102738. doi: 10.1016\/j.coi.2026.102738. Online ahead of print. ABSTRACT Antimicrobial peptides and proteins (AMPs) function as molecular rheostats of host-microbe interactions and cell-intrinsic defense. Rather than being binary effectors, they act along a continuum. At basal levels, AMPs maintain harmony with the commensal members of the microbiome, and upon pathogen encounter, &#8230; <a title=\"Antimicrobial peptides and proteins as rheostats of intestinal homeostasis and immunity\" class=\"read-more\" href=\"https:\/\/inmuno.es\/index.php\/2026\/02\/19\/antimicrobial-peptides-and-proteins-as-rheostats-of-intestinal-homeostasis-and-immunity\/\" aria-label=\"Read more about Antimicrobial peptides and proteins as rheostats of intestinal homeostasis and immunity\">Read more<\/a><\/div><\/li>\n<li><a class=\"wp-block-latest-posts__post-title\" href=\"https:\/\/inmuno.es\/index.php\/2026\/02\/18\/t-cells-in-sjogrens-disease-update-on-their-role-in-salivary-gland-pathogenesis-and-treatment\/\">T cells in Sj\u00f6gren&#8217;s disease: update on their role in salivary gland pathogenesis and treatment<\/a><div class=\"wp-block-latest-posts__post-author\">by inmunoadmin<\/div><time datetime=\"2026-02-18T06:55:56+01:00\" class=\"wp-block-latest-posts__post-date\">18 de February de 2026<\/time><div class=\"wp-block-latest-posts__post-excerpt\">Curr Opin Immunol. 2026 Feb 16;99:102739. doi: 10.1016\/j.coi.2026.102739. Online ahead of print. ABSTRACT Sj\u00f6gren&#8217;s disease (SjD) is a chronic, systemic autoimmune disease that mainly targets saliva- and tear-producing glands. T-cells are a substantial immune cell subset involved in SjD pathogenesis, including break of tolerance toward self, and constitute a major part of tissue-resident and infiltrating &#8230; <a title=\"T cells in Sj\u00f6gren&#8217;s disease: update on their role in salivary gland pathogenesis and treatment\" class=\"read-more\" href=\"https:\/\/inmuno.es\/index.php\/2026\/02\/18\/t-cells-in-sjogrens-disease-update-on-their-role-in-salivary-gland-pathogenesis-and-treatment\/\" aria-label=\"Read more about T cells in Sj\u00f6gren&#8217;s disease: update on their role in salivary gland pathogenesis and treatment\">Read more<\/a><\/div><\/li>\n<li><a class=\"wp-block-latest-posts__post-title\" href=\"https:\/\/inmuno.es\/index.php\/2026\/02\/16\/multiple-sclerosis-a-disease-or-a-syndrome\/\">Multiple sclerosis: a disease or a syndrome?<\/a><div class=\"wp-block-latest-posts__post-author\">by inmunoadmin<\/div><time datetime=\"2026-02-16T07:11:40+01:00\" class=\"wp-block-latest-posts__post-date\">16 de February de 2026<\/time><div class=\"wp-block-latest-posts__post-excerpt\">Curr Opin Immunol. 2026 Feb 14;99:102736. doi: 10.1016\/j.coi.2026.102736. Online ahead of print. ABSTRACT Multiple sclerosis (MS) is traditionally considered a chronic immune-mediated disease of the central nervous system. However, increasing evidence suggests substantial clinical, radiological, and immunopathological heterogeneity among individuals diagnosed with MS. In recent years, increasing awareness of this heterogeneity has led to a &#8230; <a title=\"Multiple sclerosis: a disease or a syndrome?\" class=\"read-more\" href=\"https:\/\/inmuno.es\/index.php\/2026\/02\/16\/multiple-sclerosis-a-disease-or-a-syndrome\/\" aria-label=\"Read more about Multiple sclerosis: a disease or a syndrome?\">Read more<\/a><\/div><\/li>\n<li><a class=\"wp-block-latest-posts__post-title\" href=\"https:\/\/inmuno.es\/index.php\/2026\/02\/15\/trpm7-channel-kinase-in-immunity-new-frontiers-of-an-emerging-therapeutic-target\/\">TRPM7 channel-kinase in immunity: new frontiers of an emerging therapeutic target<\/a><div class=\"wp-block-latest-posts__post-author\">by inmunoadmin<\/div><time datetime=\"2026-02-15T06:46:45+01:00\" class=\"wp-block-latest-posts__post-date\">15 de February de 2026<\/time><div class=\"wp-block-latest-posts__post-excerpt\">Curr Opin Immunol. 2026 Feb 13;99:102734. doi: 10.1016\/j.coi.2026.102734. Online ahead of print. ABSTRACT The cation channel and protein kinase transient receptor potential cation channel subfamily M member 7 (TRPM7) has been linked to immune homeostasis, immune cell signaling and differentiation, and inflammatory diseases. Its importance in guiding ion-mediated cellular responses, funneling discrete kinase signal transduction &#8230; <a title=\"TRPM7 channel-kinase in immunity: new frontiers of an emerging therapeutic target\" class=\"read-more\" href=\"https:\/\/inmuno.es\/index.php\/2026\/02\/15\/trpm7-channel-kinase-in-immunity-new-frontiers-of-an-emerging-therapeutic-target\/\" aria-label=\"Read more about TRPM7 channel-kinase in immunity: new frontiers of an emerging therapeutic target\">Read more<\/a><\/div><\/li>\n<li><a class=\"wp-block-latest-posts__post-title\" href=\"https:\/\/inmuno.es\/index.php\/2026\/02\/15\/minor-salivary-gland-biopsy-in-sjogrens-disease-a-diagnostic-and-prognostic-tool-toward-precision-medicine\/\">Minor salivary gland biopsy in Sjogren&#8217;s disease: a diagnostic and prognostic tool toward precision medicine<\/a><div class=\"wp-block-latest-posts__post-author\">by inmunoadmin<\/div><time datetime=\"2026-02-15T06:46:45+01:00\" class=\"wp-block-latest-posts__post-date\">15 de February de 2026<\/time><div class=\"wp-block-latest-posts__post-excerpt\">Curr Opin Immunol. 2026 Feb 13;99:102737. doi: 10.1016\/j.coi.2026.102737. Online ahead of print. ABSTRACT Minor salivary gland biopsy occupies a distinctive position in the evaluation of Sj\u00f6gren disease (SjD), offering diagnostic and prognostic insights that are rarely achievable in other systemic autoimmune conditions. It contributes essential diagnostic information, particularly for patients lacking anti-Ro\/SSA antibodies or pediatric &#8230; <a title=\"Minor salivary gland biopsy in Sjogren&#8217;s disease: a diagnostic and prognostic tool toward precision medicine\" class=\"read-more\" href=\"https:\/\/inmuno.es\/index.php\/2026\/02\/15\/minor-salivary-gland-biopsy-in-sjogrens-disease-a-diagnostic-and-prognostic-tool-toward-precision-medicine\/\" aria-label=\"Read more about Minor salivary gland biopsy in Sjogren&#8217;s disease: a diagnostic and prognostic tool toward precision medicine\">Read more<\/a><\/div><\/li>\n<li><a class=\"wp-block-latest-posts__post-title\" href=\"https:\/\/inmuno.es\/index.php\/2026\/02\/15\/cell-death-pathways-in-graft-versus-host-disease\/\">Cell death pathways in graft-versus-host disease<\/a><div class=\"wp-block-latest-posts__post-author\">by inmunoadmin<\/div><time datetime=\"2026-02-15T06:46:45+01:00\" class=\"wp-block-latest-posts__post-date\">15 de February de 2026<\/time><div class=\"wp-block-latest-posts__post-excerpt\">Curr Opin Immunol. 2026 Feb 13;99:102740. doi: 10.1016\/j.coi.2026.102740. Online ahead of print. ABSTRACT Regulated cell death, including apoptosis, necroptosis, and pyroptosis, as well as cell death arising from disrupted cellular homeostasis, such as ferroptosis and dysregulated autophagy, is implicated in cancer, autoimmunity, and transplantation biology. Graft-versus-host disease (GVHD), a major cause of morbidity and mortality &#8230; <a title=\"Cell death pathways in graft-versus-host disease\" class=\"read-more\" href=\"https:\/\/inmuno.es\/index.php\/2026\/02\/15\/cell-death-pathways-in-graft-versus-host-disease\/\" aria-label=\"Read more about Cell death pathways in graft-versus-host disease\">Read more<\/a><\/div><\/li>\n<li><a class=\"wp-block-latest-posts__post-title\" href=\"https:\/\/inmuno.es\/index.php\/2026\/02\/13\/rheumatoid-arthritis-revisiting-pathogenesis-for-prevention-stratification-and-repair\/\">Rheumatoid arthritis: revisiting pathogenesis for prevention, stratification, and repair<\/a><div class=\"wp-block-latest-posts__post-author\">by inmunoadmin<\/div><time datetime=\"2026-02-13T02:56:08+01:00\" class=\"wp-block-latest-posts__post-date\">13 de February de 2026<\/time><div class=\"wp-block-latest-posts__post-excerpt\">Curr Opin Immunol. 2026 Feb 11;99:102735. doi: 10.1016\/j.coi.2026.102735. Online ahead of print. ABSTRACT The clinical heterogeneity of rheumatoid arthritis (RA) reflects a series of dynamic immunological imbalances rather than a single dominant mechanism. In this review, we propose that RA progression is best understood as a sequence of three functional balances. The first contrasts pathogenic &#8230; <a title=\"Rheumatoid arthritis: revisiting pathogenesis for prevention, stratification, and repair\" class=\"read-more\" href=\"https:\/\/inmuno.es\/index.php\/2026\/02\/13\/rheumatoid-arthritis-revisiting-pathogenesis-for-prevention-stratification-and-repair\/\" aria-label=\"Read more about Rheumatoid arthritis: revisiting pathogenesis for prevention, stratification, and repair\">Read more<\/a><\/div><\/li>\n<li><a class=\"wp-block-latest-posts__post-title\" href=\"https:\/\/inmuno.es\/index.php\/2026\/01\/29\/malaria-in-pregnancy-at-the-frontline-a-delicate-balance\/\">Malaria in pregnancy at the frontline: a delicate balance<\/a><div class=\"wp-block-latest-posts__post-author\">by inmunoadmin<\/div><time datetime=\"2026-01-29T08:08:18+01:00\" class=\"wp-block-latest-posts__post-date\">29 de January de 2026<\/time><div class=\"wp-block-latest-posts__post-excerpt\">Curr Opin Immunol. 2026 Jan 27;99:102726. doi: 10.1016\/j.coi.2026.102726. Online ahead of print. ABSTRACT Malaria during pregnancy continues to compromise maternal, fetal, and subsequently infant health. This burden has increased in Africa, though it has decreased elsewhere. Here, we provide a concise review of recent findings on malaria in pregnancy, addressing pathogenesis, immunity, offspring outcomes, and &#8230; <a title=\"Malaria in pregnancy at the frontline: a delicate balance\" class=\"read-more\" href=\"https:\/\/inmuno.es\/index.php\/2026\/01\/29\/malaria-in-pregnancy-at-the-frontline-a-delicate-balance\/\" aria-label=\"Read more about Malaria in pregnancy at the frontline: a delicate balance\">Read more<\/a><\/div><\/li>\n<li><a class=\"wp-block-latest-posts__post-title\" href=\"https:\/\/inmuno.es\/index.php\/2026\/01\/25\/patterns-and-trends-in-sarcoidosis-an-epidemiological-perspective\/\">Patterns and trends in sarcoidosis: an epidemiological perspective<\/a><div class=\"wp-block-latest-posts__post-author\">by inmunoadmin<\/div><time datetime=\"2026-01-25T07:21:15+01:00\" class=\"wp-block-latest-posts__post-date\">25 de January de 2026<\/time><div class=\"wp-block-latest-posts__post-excerpt\">Curr Opin Immunol. 2026 Jan 23;99:102723. doi: 10.1016\/j.coi.2025.102723. Online ahead of print. ABSTRACT The incidence, prevalence, and burden of sarcoidosis is increasing worldwide. The Nordic countries have the highest incidence with lowest rates reported in Asia. In the United States, Black females have the highest incidence and prevalence of disease. The phenotypic manifestations of sarcoidosis &#8230; <a title=\"Patterns and trends in sarcoidosis: an epidemiological perspective\" class=\"read-more\" href=\"https:\/\/inmuno.es\/index.php\/2026\/01\/25\/patterns-and-trends-in-sarcoidosis-an-epidemiological-perspective\/\" aria-label=\"Read more about Patterns and trends in sarcoidosis: an epidemiological perspective\">Read more<\/a><\/div><\/li>\n<li><a class=\"wp-block-latest-posts__post-title\" href=\"https:\/\/inmuno.es\/index.php\/2026\/01\/25\/evaluating-the-pandemic-potential-of-zika-virus-in-a-changing-global-landscape\/\">Evaluating the pandemic potential of Zika virus in a changing global landscape<\/a><div class=\"wp-block-latest-posts__post-author\">by inmunoadmin<\/div><time datetime=\"2026-01-25T07:21:15+01:00\" class=\"wp-block-latest-posts__post-date\">25 de January de 2026<\/time><div class=\"wp-block-latest-posts__post-excerpt\">Curr Opin Immunol. 2026 Jan 22;99:102724. doi: 10.1016\/j.coi.2026.102724. Online ahead of print. ABSTRACT As of 2024, the World Health Organization declared the Zika virus (ZIKV), an emerging flavivirus, as a high-priority pathogen with the potential to cause future Public Health Emergencies of International Concern. Although the last major outbreak of ZIKV occurred in 2015-2016, ongoing &#8230; <a title=\"Evaluating the pandemic potential of Zika virus in a changing global landscape\" class=\"read-more\" href=\"https:\/\/inmuno.es\/index.php\/2026\/01\/25\/evaluating-the-pandemic-potential-of-zika-virus-in-a-changing-global-landscape\/\" aria-label=\"Read more about Evaluating the pandemic potential of Zika virus in a changing global landscape\">Read more<\/a><\/div><\/li>\n<li><a class=\"wp-block-latest-posts__post-title\" href=\"https:\/\/inmuno.es\/index.php\/2026\/01\/24\/a-comprehensive-study-on-the-effect-of-alglucosidase-alpha-and-immunomodulation-on-survival-motor-and-cardiac-outcome-creatine-kinase-and-antibody-titers-in-classic-infantile-pompe-disease-the-monz\/\">A comprehensive study on the effect of alglucosidase alpha and immunomodulation on survival, motor and cardiac outcome, creatine kinase and antibody titers in classic infantile Pompe disease: the Monza experience<\/a><div class=\"wp-block-latest-posts__post-author\">by inmunoadmin<\/div><time datetime=\"2026-01-24T06:47:44+01:00\" class=\"wp-block-latest-posts__post-date\">24 de January de 2026<\/time><div class=\"wp-block-latest-posts__post-excerpt\">Curr Opin Immunol. 2026 Jan 22;99:102725. doi: 10.1016\/j.coi.2026.102725. Online ahead of print. ABSTRACT We report on 13 classic infantile Pompe patients, including four cross-reactive immunological material negative (31%), treated with alglucosidase alpha (rhGAA) at Fondazione IRCCS San Gerardo, Monza, between 2003 and 2024. Median age at rhGAA initiation was 3.3 months, with nine patients (69%) &#8230; <a title=\"A comprehensive study on the effect of alglucosidase alpha and immunomodulation on survival, motor and cardiac outcome, creatine kinase and antibody titers in classic infantile Pompe disease: the Monza experience\" class=\"read-more\" href=\"https:\/\/inmuno.es\/index.php\/2026\/01\/24\/a-comprehensive-study-on-the-effect-of-alglucosidase-alpha-and-immunomodulation-on-survival-motor-and-cardiac-outcome-creatine-kinase-and-antibody-titers-in-classic-infantile-pompe-disease-the-monz\/\" aria-label=\"Read more about A comprehensive study on the effect of alglucosidase alpha and immunomodulation on survival, motor and cardiac outcome, creatine kinase and antibody titers in classic infantile Pompe disease: the Monza experience\">Read more<\/a><\/div><\/li>\n<li><a class=\"wp-block-latest-posts__post-title\" href=\"https:\/\/inmuno.es\/index.php\/2026\/01\/16\/optimizing-patient-reported-outcomes-for-sarcoidosis\/\">Optimizing patient-reported outcomes for sarcoidosis<\/a><div class=\"wp-block-latest-posts__post-author\">by inmunoadmin<\/div><time datetime=\"2026-01-16T23:47:51+01:00\" class=\"wp-block-latest-posts__post-date\">16 de January de 2026<\/time><div class=\"wp-block-latest-posts__post-excerpt\">Curr Opin Immunol. 2026 Jan 14;99:102720. doi: 10.1016\/j.coi.2025.102720. Online ahead of print. ABSTRACT Patients with sarcoidosis can present with a wide range of symptoms that impact their quality of life (QoL). QoL represents one of the most important treatment priorities for patients. Therefore, measuring what matters to patients is of great importance, though it can &#8230; <a title=\"Optimizing patient-reported outcomes for sarcoidosis\" class=\"read-more\" href=\"https:\/\/inmuno.es\/index.php\/2026\/01\/16\/optimizing-patient-reported-outcomes-for-sarcoidosis\/\" aria-label=\"Read more about Optimizing patient-reported outcomes for sarcoidosis\">Read more<\/a><\/div><\/li>\n<li><a class=\"wp-block-latest-posts__post-title\" href=\"https:\/\/inmuno.es\/index.php\/2026\/01\/15\/elderly-onset-rheumatoid-arthritis-as-a-distinct-entity-mechanisms-manifestations-and-treatment\/\">Elderly-onset rheumatoid arthritis as a distinct entity: mechanisms, manifestations, and treatment<\/a><div class=\"wp-block-latest-posts__post-author\">by inmunoadmin<\/div><time datetime=\"2026-01-15T22:29:01+01:00\" class=\"wp-block-latest-posts__post-date\">15 de January de 2026<\/time><div class=\"wp-block-latest-posts__post-excerpt\">Curr Opin Immunol. 2026 Jan 13;99:102721. doi: 10.1016\/j.coi.2025.102721. Online ahead of print. ABSTRACT Elderly-onset rheumatoid arthritis (EORA), defined as onset at \u226560 years, is a clinically distinct and increasingly prevalent subset of rheumatoid arthritis (RA). This review synthesizes evidence that EORA is not merely late-onset RA but a pathogenically unique entity, driven by immune aging, &#8230; <a title=\"Elderly-onset rheumatoid arthritis as a distinct entity: mechanisms, manifestations, and treatment\" class=\"read-more\" href=\"https:\/\/inmuno.es\/index.php\/2026\/01\/15\/elderly-onset-rheumatoid-arthritis-as-a-distinct-entity-mechanisms-manifestations-and-treatment\/\" aria-label=\"Read more about Elderly-onset rheumatoid arthritis as a distinct entity: mechanisms, manifestations, and treatment\">Read more<\/a><\/div><\/li>\n<li><a class=\"wp-block-latest-posts__post-title\" href=\"https:\/\/inmuno.es\/index.php\/2026\/01\/15\/a-critical-look-at-animal-and-cellular-models-in-autoinflammatory-diseases\/\">A critical look at animal and cellular models in autoinflammatory diseases<\/a><div class=\"wp-block-latest-posts__post-author\">by inmunoadmin<\/div><time datetime=\"2026-01-15T22:29:01+01:00\" class=\"wp-block-latest-posts__post-date\">15 de January de 2026<\/time><div class=\"wp-block-latest-posts__post-excerpt\">Curr Opin Immunol. 2026 Jan 13;99:102719. doi: 10.1016\/j.coi.2025.102719. Online ahead of print. ABSTRACT Autoinflammatory diseases (AIDs) comprise a diverse group of conditions arising from dysregulated immune control due to congenital or acquired genetic abnormalities in innate immune pathways, and patients typically require lifelong treatment. Owing to their rarity, access to patient samples is limited, making &#8230; <a title=\"A critical look at animal and cellular models in autoinflammatory diseases\" class=\"read-more\" href=\"https:\/\/inmuno.es\/index.php\/2026\/01\/15\/a-critical-look-at-animal-and-cellular-models-in-autoinflammatory-diseases\/\" aria-label=\"Read more about A critical look at animal and cellular models in autoinflammatory diseases\">Read more<\/a><\/div><\/li>\n<li><a class=\"wp-block-latest-posts__post-title\" href=\"https:\/\/inmuno.es\/index.php\/2026\/01\/15\/new-autoantibodies-in-sjogrens-disease\/\">New autoantibodies in Sj\u00f6gren&#8217;s disease<\/a><div class=\"wp-block-latest-posts__post-author\">by inmunoadmin<\/div><time datetime=\"2026-01-15T22:29:00+01:00\" class=\"wp-block-latest-posts__post-date\">15 de January de 2026<\/time><div class=\"wp-block-latest-posts__post-excerpt\">Curr Opin Immunol. 2026 Jan 13;99:102722. doi: 10.1016\/j.coi.2025.102722. Online ahead of print. ABSTRACT Primary Sj\u00f6gren&#8217;s disease (SjD) is a systemic autoimmune disorder where diagnosis relies on the presence of Ro\/SS-A and La\/SS-B autoantibodies. However, approximately one-third of SjD patients are seronegative, often requiring an invasive minor salivary gland biopsy, which can lead to significant diagnostic &#8230; <a title=\"New autoantibodies in Sj\u00f6gren&#8217;s disease\" class=\"read-more\" href=\"https:\/\/inmuno.es\/index.php\/2026\/01\/15\/new-autoantibodies-in-sjogrens-disease\/\" aria-label=\"Read more about New autoantibodies in Sj\u00f6gren&#8217;s disease\">Read more<\/a><\/div><\/li>\n<li><a class=\"wp-block-latest-posts__post-title\" href=\"https:\/\/inmuno.es\/index.php\/2026\/01\/11\/a-throwback-on-25-years-in-pannexin-research\/\">A throwback on 25 years in pannexin research<\/a><div class=\"wp-block-latest-posts__post-author\">by inmunoadmin<\/div><time datetime=\"2026-01-11T06:56:32+01:00\" class=\"wp-block-latest-posts__post-date\">11 de January de 2026<\/time><div class=\"wp-block-latest-posts__post-excerpt\">Curr Opin Immunol. 2026 Jan 9;99:102718. doi: 10.1016\/j.coi.2025.102718. Online ahead of print. ABSTRACT Cellular channels consisting of pannexins facilitate signaling between the intracellular and extracellular environment. In this respect, pannexin channel opening serves as a pivotal trigger for both inflammatory processes and cell death. While pannexin channels also contribute to normal physiological functions, their roles &#8230; <a title=\"A throwback on 25 years in pannexin research\" class=\"read-more\" href=\"https:\/\/inmuno.es\/index.php\/2026\/01\/11\/a-throwback-on-25-years-in-pannexin-research\/\" aria-label=\"Read more about A throwback on 25 years in pannexin research\">Read more<\/a><\/div><\/li>\n<li><a class=\"wp-block-latest-posts__post-title\" href=\"https:\/\/inmuno.es\/index.php\/2026\/01\/11\/the-role-of-stromal-cell-immunobiology-in-understanding-and-managing-sjogrens-disease\/\">The role of stromal cell immunobiology in understanding and managing Sj\u00f6gren&#8217;s disease<\/a><div class=\"wp-block-latest-posts__post-author\">by inmunoadmin<\/div><time datetime=\"2026-01-11T06:56:32+01:00\" class=\"wp-block-latest-posts__post-date\">11 de January de 2026<\/time><div class=\"wp-block-latest-posts__post-excerpt\">Curr Opin Immunol. 2026 Jan 9;99:102714. doi: 10.1016\/j.coi.2025.102714. Online ahead of print. ABSTRACT Sj\u00f6gren&#8217;s disease (SjD) is a systemic, heterogeneous autoimmune disorder, clinically dominated by dryness symptoms resulting from inflammatory infiltration of exocrine glands. To date, no validated and resolutive therapeutic strategies are available. Stromal cells are increasingly recognized as critical players in SjD pathogenesis. &#8230; <a title=\"The role of stromal cell immunobiology in understanding and managing Sj\u00f6gren&#8217;s disease\" class=\"read-more\" href=\"https:\/\/inmuno.es\/index.php\/2026\/01\/11\/the-role-of-stromal-cell-immunobiology-in-understanding-and-managing-sjogrens-disease\/\" aria-label=\"Read more about The role of stromal cell immunobiology in understanding and managing Sj\u00f6gren&#8217;s disease\">Read more<\/a><\/div><\/li>\n<li><a class=\"wp-block-latest-posts__post-title\" href=\"https:\/\/inmuno.es\/index.php\/2026\/01\/11\/metabolomic-signaling-in-sarcoidosis-pathogenesis\/\">Metabolomic signaling in sarcoidosis pathogenesis<\/a><div class=\"wp-block-latest-posts__post-author\">by inmunoadmin<\/div><time datetime=\"2026-01-11T06:56:32+01:00\" class=\"wp-block-latest-posts__post-date\">11 de January de 2026<\/time><div class=\"wp-block-latest-posts__post-excerpt\">Curr Opin Immunol. 2026 Jan 9;99:102715. doi: 10.1016\/j.coi.2025.102715. Online ahead of print. ABSTRACT Sarcoidosis is a multisystem inflammatory disorder characterized by noncaseating granulomas in various organs, predominantly affecting the lungs and lymphatic system. Although the etiology of sarcoidosis remains unknown, it is believed to result from an abnormal immune response triggered by environmental agents in &#8230; <a title=\"Metabolomic signaling in sarcoidosis pathogenesis\" class=\"read-more\" href=\"https:\/\/inmuno.es\/index.php\/2026\/01\/11\/metabolomic-signaling-in-sarcoidosis-pathogenesis\/\" aria-label=\"Read more about Metabolomic signaling in sarcoidosis pathogenesis\">Read more<\/a><\/div><\/li>\n<li><a class=\"wp-block-latest-posts__post-title\" href=\"https:\/\/inmuno.es\/index.php\/2026\/01\/10\/markers-predicting-lymphoma-development-in-sjogren-disease-current-status-and-future-perspectives\/\">Markers predicting lymphoma development in Sj\u00f6gren disease: current status and future perspectives<\/a><div class=\"wp-block-latest-posts__post-author\">by inmunoadmin<\/div><time datetime=\"2026-01-10T06:39:05+01:00\" class=\"wp-block-latest-posts__post-date\">10 de January de 2026<\/time><div class=\"wp-block-latest-posts__post-excerpt\">Curr Opin Immunol. 2026 Jan 8;99:102717. doi: 10.1016\/j.coi.2025.102717. Online ahead of print. ABSTRACT We aim to present recent advancements in predictive markers for lymphomagenesis in SjD, concisely organize existing knowledge, and identify corresponding unmet needs and future perspectives. First, we briefly describe the mechanisms of lymphomagenesis in SjD. Followingly, the reasons justifying the importance of &#8230; <a title=\"Markers predicting lymphoma development in Sj\u00f6gren disease: current status and future perspectives\" class=\"read-more\" href=\"https:\/\/inmuno.es\/index.php\/2026\/01\/10\/markers-predicting-lymphoma-development-in-sjogren-disease-current-status-and-future-perspectives\/\" aria-label=\"Read more about Markers predicting lymphoma development in Sj\u00f6gren disease: current status and future perspectives\">Read more<\/a><\/div><\/li>\n<li><a class=\"wp-block-latest-posts__post-title\" href=\"https:\/\/inmuno.es\/index.php\/2026\/01\/10\/emerging-diagnostic-techniques-in-sarcoidosis-a-path-forward\/\">Emerging diagnostic techniques in sarcoidosis: a path forward<\/a><div class=\"wp-block-latest-posts__post-author\">by inmunoadmin<\/div><time datetime=\"2026-01-10T06:39:05+01:00\" class=\"wp-block-latest-posts__post-date\">10 de January de 2026<\/time><div class=\"wp-block-latest-posts__post-excerpt\">Curr Opin Immunol. 2026 Jan 8;99:102716. doi: 10.1016\/j.coi.2025.102716. Online ahead of print. ABSTRACT Sarcoidosis is a complex and heterogenous disease of which the diagnosis is based on clinical and radiological findings, histopathology showing non-caseating granulomas, and exclusion of other granulomatous diseases. Several tools are well established in the diagnostic pathway, such as pulmonary function tests, &#8230; <a title=\"Emerging diagnostic techniques in sarcoidosis: a path forward\" class=\"read-more\" href=\"https:\/\/inmuno.es\/index.php\/2026\/01\/10\/emerging-diagnostic-techniques-in-sarcoidosis-a-path-forward\/\" aria-label=\"Read more about Emerging diagnostic techniques in sarcoidosis: a path forward\">Read more<\/a><\/div><\/li>\n<li><a class=\"wp-block-latest-posts__post-title\" href=\"https:\/\/inmuno.es\/index.php\/2025\/12\/24\/mapping-the-b-cell-axis-in-sjogrens-disease-repertoire-microenvironment-and-potential-routes-to-precision-treatment\/\">Mapping the B-cell axis in Sj\u00f6gren&#8217;s disease: repertoire, microenvironment, and potential routes to precision treatment<\/a><div class=\"wp-block-latest-posts__post-author\">by inmunoadmin<\/div><time datetime=\"2025-12-24T07:29:04+01:00\" class=\"wp-block-latest-posts__post-date\">24 de December de 2025<\/time><div class=\"wp-block-latest-posts__post-excerpt\">Curr Opin Immunol. 2025 Dec 22;98:102712. doi: 10.1016\/j.coi.2025.102712. Online ahead of print. ABSTRACT Sj\u00f6gren&#8217;s disease (SjD) is a chronic autoimmune disorder in which sustained B-cell activation drives glandular injury and systemic complications. Epithelial stress and interferon tone amplify B-cell activating factor (BAFF)-dependent survival, skewing selection toward autoreactive clones in both glands and blood. In addition, &#8230; <a title=\"Mapping the B-cell axis in Sj\u00f6gren&#8217;s disease: repertoire, microenvironment, and potential routes to precision treatment\" class=\"read-more\" href=\"https:\/\/inmuno.es\/index.php\/2025\/12\/24\/mapping-the-b-cell-axis-in-sjogrens-disease-repertoire-microenvironment-and-potential-routes-to-precision-treatment\/\" aria-label=\"Read more about Mapping the B-cell axis in Sj\u00f6gren&#8217;s disease: repertoire, microenvironment, and potential routes to precision treatment\">Read more<\/a><\/div><\/li>\n<li><a class=\"wp-block-latest-posts__post-title\" href=\"https:\/\/inmuno.es\/index.php\/2025\/12\/24\/diet-derived-microbial-metabolites-as-regulators-of-immune-function\/\">Diet-derived microbial metabolites as regulators of immune function<\/a><div class=\"wp-block-latest-posts__post-author\">by inmunoadmin<\/div><time datetime=\"2025-12-24T07:29:04+01:00\" class=\"wp-block-latest-posts__post-date\">24 de December de 2025<\/time><div class=\"wp-block-latest-posts__post-excerpt\">Curr Opin Immunol. 2025 Dec 22;98:102713. doi: 10.1016\/j.coi.2025.102713. Online ahead of print. ABSTRACT The intestinal microbiota transforms dietary components into bioactive metabolites that profoundly influence mucosal and systemic immunity. Short-chain fatty acids, secondary bile acids and tryptophan-derived indoles are among the most studied microbial metabolites shaping T, B and innate immune cell functions through a &#8230; <a title=\"Diet-derived microbial metabolites as regulators of immune function\" class=\"read-more\" href=\"https:\/\/inmuno.es\/index.php\/2025\/12\/24\/diet-derived-microbial-metabolites-as-regulators-of-immune-function\/\" aria-label=\"Read more about Diet-derived microbial metabolites as regulators of immune function\">Read more<\/a><\/div><\/li>\n<li><a class=\"wp-block-latest-posts__post-title\" href=\"https:\/\/inmuno.es\/index.php\/2025\/12\/21\/complement-deficiencies-and-infections\/\">Complement deficiencies and infections<\/a><div class=\"wp-block-latest-posts__post-author\">by inmunoadmin<\/div><time datetime=\"2025-12-21T08:27:59+01:00\" class=\"wp-block-latest-posts__post-date\">21 de December de 2025<\/time><div class=\"wp-block-latest-posts__post-excerpt\">Curr Opin Immunol. 2025 Dec 19;98:102711. doi: 10.1016\/j.coi.2025.102711. Online ahead of print. ABSTRACT The complement system is a central component of innate immunity, mediating opsonization, chemotaxis, cytolysis, and shaping adaptive responses. Deficiencies in complement proteins, whether inherited or acquired, predispose to severe infections, particularly with encapsulated bacteria such as Neisseria meningitidis and Streptococcus pneumoniae. Although &#8230; <a title=\"Complement deficiencies and infections\" class=\"read-more\" href=\"https:\/\/inmuno.es\/index.php\/2025\/12\/21\/complement-deficiencies-and-infections\/\" aria-label=\"Read more about Complement deficiencies and infections\">Read more<\/a><\/div><\/li>\n<\/ul>","protected":false},"excerpt":{"rendered":"","protected":false},"author":1,"featured_media":16677,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"footnotes":""},"class_list":["post-16676","page","type-page","status-publish","has-post-thumbnail"],"_links":{"self":[{"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/pages\/16676","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/comments?post=16676"}],"version-history":[{"count":2,"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/pages\/16676\/revisions"}],"predecessor-version":[{"id":16683,"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/pages\/16676\/revisions\/16683"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/media\/16677"}],"wp:attachment":[{"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/media?parent=16676"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}